

Curriculum Vitae

Alan Lee Robin, MD

Associate Professor Ophthalmology, Johns Hopkins University (1986-2015)

Associate Professor Ophthalmology, Johns Hopkins University, Emeritus
(December 1, 2015, to present)

Associate Professor International Health, Johns Hopkins University (1991-present)

Clinical Professor, Ophthalmology, University of Maryland (1998-2012, and 2014-2017)

Professor of Ophthalmology, Veteran's Administration System (1999-present)

Adjunct Professor, University of Michigan (2014 to present)

Date: March 8, 2018

I. PERSONAL DATA

II. PERSONAL DATA Contact Information:

Contact Information

Business Address 6115 Falls Road, Suite 333
Baltimore, MD 21209-2226
Business Phone +1-410-377-2422
Business Fax 1-410-377-7960
Email arobin@glaucomaexpert.com
Foreign Languages Italian (working knowledge)

II. EDUCATION AND PROFESSIONAL TRAINING

1962-1966 New Trier High School, Winnetka, Illinois.
1966-1970 Yale University, New Haven, Connecticut; B.A.
1970-1974 Tufts University School of Medicine, Boston,
Massachusetts; M.D.

III. POST GRADUATE EDUCATION

1974-1975 Rochester General Hospital, Rochester, New York, Internal Medicine Intern.
 1975-1978 Greater Baltimore Medical Center, Baltimore, Maryland; Resident and Chief Resident, Ophthalmology.
 1978-1979 Glaucoma Service, Wilmer Institute, Johns Hopkins University; Baltimore, Maryland. Glaucoma Fellow

IV. CERTIFICATION

American Board of Ophthalmology 1979 Active

V. LICENSURE

New York 1975 Inactive
 Maryland 1975 Active
 Pennsylvania 1990 Active

VI. EMPLOYMENT HISTORY

Academic Employment

No Full-Time Academic Employment
 Part-time employment, University of Michigan

Other Employment

Self-employed – private practice, July 1979 to present
 Alan L. Robin, MD PA

VII. PROFESSIONAL SOCIETIES

1979-1989 Baltimore City Medical Society, Member
 1979-Present Association For Research in Vision and Ophthalmology (ARVO)
 1079-Present American Academy Of Ophthalmology (AAO)
 1979-1995 Maryland Society for Eye Physicians and Surgeons, Member
 1982-1990 Annual Glaucomatologists Learning Ensemble (ANGLE), Member
 1984-1986 Maryland Society for the Prevention of Blindness, Vice-President
 1986-Present American Glaucoma Society, Charter Member
 1986-Present International Association to Prevent Blindness, Member
 1991-1996 Chairman, American Academy of Ophthalmology subcommittee on Ophthalmic Instruments and Maintenance (Committee on International Ophthalmology)
 1991-1998 Member, American Academy of Ophthalmology committee on International Ophthalmology
 1991-1993 Baltimore County Medical Society
 1991-1992 Member, Program Committee, American Glaucoma Society
 1994-1998 Association for Ocular Pharmacology and Therapeutics

- 1995-2001 Member, American Academy of Ophthalmology Committee on Procedure Assessments
- 1996-2001 Board Member, International Eye Foundation
- 1997-2005 Member, American Society for Cataract and Refractive Surgeons, Member Glaucoma Special Interest Group
- 1997-2001 Member, International Advisory Committee, TBI/Tissue Banks International
- 1994-present Executive Committee, Greater Baltimore Medical Center Ophthalmology Residency Program
- 1996- 2004 Consultant, Maryland Board of Optometry Quality Enhancement and Improvement Committee.
- 1998- 2005 Member, Curriculum committee, ORBIS International
- 1999- Present Board of Trustees, Friends Of Aravind Eye Hospital Charitable Trust
- 2008- 2010 Foundation Fighting Blindness Baltimore Chapter, board of directors

VII. HONORS AND AWARDS

- 1978 Greater Baltimore Medical Center, Resident Publication Award
- 1978-1979 Heed Fellow
- 1979 ARVO Travel Award.
- 1982 First Prize, Scientific Exhibit. The Use of Lasers in Glaucoma. American Academy of Ophthalmology, San Francisco
- 1988 American Academy of Ophthalmology, Honor Award
- 1988 Alcon Laboratories, Research Excellence Award
- 1989 American Ophthalmological Society, Associate Member
- 1989 Honorary Member, Nepal Ophthalmological Society
- 1992 Honorary Member, Indian Glaucoma Society
- 1997 Janice Kushner Memorial Lecture for International Glaucoma Association (London, England)
- 1998 American Academy of Ophthalmology Senior Honor Award
- 1998 Attending Of The Year: Greater Baltimore Medical Center, Baltimore, Maryland
- 2002 Who's Who in the 21st Century
- 2002 Who's Who in America
- 2002- 2011 America's Top Doctors
- 2002 *Baltimore Magazine's* Baltimore's Top Doctors
- 2002 Program Director, Joint Bloomberg School of Public Health and Wilmer Institute Symposium on Ethnicity and Glaucoma
- 2003 Life Time Member Global Directory of Who's Who
- 2002-2008 Scientific Advisory Board, Alcon Laboratories, Inc.
- 2004 American Glaucoma Society Nominee for the American Academy of Ophthalmology Humanitarian Award
- 2005 American Academy of Ophthalmology Outstanding Humanitarian Service

Award

2005-2010 Best Doctors in Maryland

2006 Membership in Glaucoma Research Society

2007 Top Winner, Maryland Health Care Hero, March, 2007

2007 Baltimore Magazine Top Doctor

2008 Hawaiian Eye Meeting Speaker of the Day

2010 Hawaiian Eye Meeting Speaker of the Day

2010 Association of Research in Vision and Ophthalmology Silver Fellow Award

2010 American Academy of Ophthalmology Secretariat Award

2010 Baltimore Magazine Top Doctor

2011 Kapetansky Lecture, Midwest Glaucoma Symposium, June 2011

2011-2 Best Doctors of America

2012 US News And World Reports: Top Doctor

2012 Dr G.Venkataswamy Endowment Oration Award. Madurai, India, October 2012

2013 First International Scholar in Residence, University of Michigan, Kellogg Eye Institute

2014 Awardee, 2014 American Glaucoma Society Humanitarian Award

2016 American Academy of Ophthalmology Life Time Achievement Award

2016 Nominee for Heed-Gutman Award

VIII. CLINICAL ACTIVITIES

Principal Investigator of the First Scientific Prevalence Study in a Developing Country

Founder of the Indian Glaucoma Society

Developed Alpha-agonists in the therapy of Glaucoma

Developed ND:YAG laser iridotomy

First to validate the use of intraocular lenses in less developed nations

First to perform dose response curve for mitomycin C for filtration surgery

First to video and describe problems with eye drop administration

Created and developed the glaucoma service, at Aravind Eye Hospital, Kathmandu, Nepal

Collaboration with Faculty of Tilganga Eye Institute, Kathmandu, Nepal

Co-Director, Quality Care Committee, Superior Vision

Private Practice with offices in Baltimore, Havre De Grace, Hagerstown and York, PA.

2010-Present Advisory Board, Tissue Banks International/International Federation of Eye and Tissue Banks

2011-2015 Member, American Glaucoma Society Health Care Policy and Advocacy Subcommittee of the Patient Care committee

1979-1995 Member, American Medical Society

2013-Present Member, American Medical Society

2015-2016 GBMC chairman search committee

2015-Present American Glaucoma Society FDA Minimally Invasive Glaucoma Surgery (MIGS) Advisory Committee

2016-2017 American Glaucoma Society Patient Care Committee-Regulatory Agency Interaction Subcommittee

- 2016-present American Glaucoma Society PCC - Quality, Efficiency and Performance Measures Subcommittee
- 2016-present American Society of Cataract and Refractive Surgeons
- 2018-present American Glaucoma Society Political Awareness & Advocacy Subcommittee

IX. ADMINISTRATIVE SERVICES

Institutional Services

- 1980-1982 Pharmacy and Therapeutics Committee, Greater Baltimore Medical Center: Member
- 1981-2000 Glaucoma Service, Sinai Hospital: Co-director
- 1985-1990 Institutional Review Board, Sinai Hospital: Member
- 1988-1990 Executive Advisory Panel, Department of Ophthalmology, Sinai Hospital: Member
- 1988-1994 Pharmacy and Therapeutics Committee, Greater Baltimore Medical Center: Member
- 1992-1994 Surgical Quality of Care Committee, Greater Baltimore Medical Center, Member.
- 1992-Present Quality Assurance Committee, Maryland Eye Care, Member.
- 1994-2000 Advisory Board, Greater Baltimore Medical Center, Department of Ophthalmology

Local and National

- 1982-2008 Co-founder and Moderator, Midwinter Glaucoma Symposium
- 1982-1992 Editor, Proceedings of the Midwinter Glaucoma Symposium
- 1984-1988 Coherent Medical, Medical Advisory Board
- 1984-1986 Maryland Society for the Prevention of Blindness, Vice-President
- 1986-Present American Glaucoma Society, Charter Member
- 1988-1994 Allergan Inc, Medical Advisory Board
- 1988-2008 Alcon Laboratories Inc, Medical Advisory Board
- 1991-1996 Chairman, American Academy of Ophthalmology subcommittee on Ophthalmic Instruments and Maintenance (Committee on International Ophthalmology)
- 1991-1998 Member, American Academy of Ophthalmology committee on International Ophthalmology
- 1991-1992 Member, Program Committee, American Glaucoma Society
- 1995-2001 Member, American Academy of Ophthalmology Committee on Procedure Assessments
- 1996-2001 Board Member, International Eye Foundation
- 1997-2005 Member, American Society for Cataract and Refractive Surgeons, Member Glaucoma Special Interest Group
- 1996- 2004 Consultant, Maryland Board of Optometry Quality Enhancement and

Improvement Committee.

1998- 2005 Member, Curriculum committee, ORBIS International

1999- Present Board of Trustees, Friends Of Aravind Eye Hospital Charitable Trust

2008- 2010 Foundation Fighting Blindness Baltimore Chapter, board of directors

2010-Present Advisory Board, Tissue Banks International/International Federation of Eye and Tissue Banks

2011-Present Member, American Glaucoma Society Health Care Policy and Advocacy Subcommittee of the Patient Care committee

2011-Present Consultant, Merck

2011-Present Consultant Allergan Pharmaceuticals.

2011-Present Consultant and Scientific Advisory board Aerie Pharmaceuticals

2011-2013 Consultant QLT

2009-Present Examiner, American Board of Ophthalmology

2011-Present Question Writing Committee, American Board of Ophthalmology

1983-Present Archives of Ophthalmology, Editorial Reviewer

1985-Present Ophthalmology, Editorial Reviewer

1985-1989 Ophthalmic Laser Therapy, Editorial Board

1986-1997 American Society of Hospital Pharmacists, Reviewer for AHFS Drug Information

1988-Present American Journal of Ophthalmology, Editorial Reviewer

1996-Present Ophthalmic Epidemiology, Editorial Reviewer

1994-Present Journal of Glaucoma, Editorial Reviewer

1988-Present World Health Organization, Consultant

2011-Present Hilton Foundation, Steering Committee, Developing a Strategy to Attack Cataract Blindness in Sub-Saharan Africa

1988-Present Nepal Eye Hospital, Katmandu, Nepal; Glaucoma Advisory Panel

1989-Present Aravind Medical Center, Madurai, India; Glaucoma Consultant and Co-Director Glaucoma Center

1995-Present Editorial Advisory Board, *Primary Care Optometry News*

1995- 9 Guest Editor, *Journal of Glaucoma*,

1995- Present Glaucoma Editorial Panel, *Ocular Surgery News*

1996- Present Editorial Panel, *Eye World News*

1997- Present Editorial Panel, *Review of Ophthalmology*

1997- 2005 Member Special Interest Panel, American Society of Cataract and Refractive Surgeons

1998- 2000 Present Editorial Panel, *Ophthalmology Capsule and Comment*

1998- 2002 Editorial Panel, *Graefe's Archive of Ophthalmology*

2000- Present Editorial Panel *Indian Journal of Ophthalmology*

2001-2002 Chief Medical Editor, *Vision and Aging*

2002-2005 Chief Medical Editor, *Glaucoma Management News*

2004-Present Present Editorial Board, *Eye World News*

2004 -Present Editorial Board: *Glaucoma Today*

2004 - 2008 Present Editorial Board: *Ophthalmologia*

2012-13 Section Editor, International Section, *Glaucoma Today*

2014-Present Wynn Institute for Vision Research Advisory Board

X. TEACHING SERVICE

Johns Hopkins University:

Fellowship trainer 1979-2000

Resident Education 1979-2013

Collaboration with

Undergrad & 2013-present

Medical

Students

University of Maryland

Fellowship co-director 1998-2003

Resident teaching 1998-present

University of Michigan

Fellowship Training 2014-present

Medical School Education 2012-present

XI. Grant Support

- | | |
|-----------|---|
| 1979-1983 | RO1-EY-01554, Uses of lasers in glaucoma, NEI, co-principal investigator |
| 1981-1984 | Allergan, Topical flurbiprofen and the immediate postoperative intraocular pressure elevation following argon laser trabeculoplasty in primary and secondary open-angle glaucomas, principal investigator |
| 1981-1984 | Merck, Sharp & Dohme, Effect of indomethacin on side effects of laser trabeculoplasty, principal investigator |
| 1981-1987 | RO1-EY-01554 Predictive and diagnostic screening test for glaucoma, NEI, co-investigator |
| 1983-1986 | Allergan, Topical levobunolol in the therapy of open-angle glaucoma, principal investigator |
| 1983-1988 | Coherent Medical, The development of a portable Q-switched Nd:YAG laser for the therapy of angle-closure glaucoma, principal investigator |

- 1983-1988 Coherent Medical, An evaluation of the Q-switched Nd:YAG laser for the therapies of angle-closure and open-angle glaucoma, principal investigator
- 1984-1995 Alcon and Coherent Medical, The utilization of a portable Q-switched Nd:YAG laser and topical apraclonidine for therapy of open-angle glaucoma in underdeveloped nations, principal investigator
- 1984-1993 Alcon, Apraclonidine HCL in the therapy of the immediate postoperative intraocular pressure elevation following anterior segment laser therapy, principal investigator
- 1988-1990 Alcon, Apraclonidine HCL: Central nervous system and cardiovascular effects and plasma levels, principal investigator
- 1988-1989 Allergan, The evaluation of levobunolol hydrochloride as a once daily therapeutic agent for chronic open-angle glaucoma, principal investigator
- 1988-1995 Alcon, Apraclonidine HCL: Efficacy as both a primary and an adjunctive agent for the therapy of chronic glaucomas, principal investigator
- 1988-1989 Allergan, the evaluation of the low dose clonidine rod as a therapeutic agent to prevent the acute transient intraocular pressure rise following laser therapy for glaucoma, principal investigator
- 1989-1990 Iolab Pharmaceuticals, Evaluation of the Effectiveness of Thymoxamine in the Reversal of Phenylephrine Induced Mydriasis, principal investigator.
- 1989- 1990 Allergan Pharmaceuticals, Once-daily levobunolol versus twice daily 0.5% therapy with diurnal measurement of intraocular pressure, principal investigator
- 1989-Present Developing a model glaucoma teaching and training center in the third world. Aravind Eye Hospital, Madurai, India, Principal Investigator.
- 1989-1995 Allergan Pharmaceuticals, Development of AGN 190342-LF (Brimonidine) as an Alpha Agonist to treat glaucoma, eliminate the postoperative intraocular pressure elevation, and assess its safety, principal investigator

- 1990-1994 Zeiss, Evaluate the reproducibility, autoregistration, and feasibility of using the Zeiss Confocal Laser Scanning Ophthalmoscope in the detection of progressive optic nerve damage and detecting pathologic optic nerve and retinal features, principal investigator
- 1990-2001 Alcon Laboratories, The Evaluation and Development of ALO 4414A as a New Topical Carbonic Anhydrase Inhibitor, principal investigator
- 1991-1997 The evaluation of a dose response of mitomycin C when used as an adjunctive agent in primary filtration surgery. Aravind Eye Hospital, Principal Investigator.
- 1992-2005 Development of a population based prevalence study in Tamil Nadu India to detect the leading causes of visual disability. Seva Foundation and Aravind Eye Hospital, principal investigator
- 1992-1994 A six month randomized double masked comparison of PhXA41 (latanoprost) to timolol in patients with open angle glaucoma and ocular hypertension. A multi-centered study in the United States. Kabi Pharmaceuticals.
- 1994- 1995 The use of a Prostaglandin D to topically lower intraocular pressure. Alcon Laboratories, Principal Investigator.
- 1994- 2009 The evaluation of anecortave acetate in human glucocorticoid glaucoma. Alcon Laboratories.
- 1994 - 1995 The evaluation of the safety, comfort, and plasma levels of anecortave in humans. Alcon Laboratories
- 1995-2009 The evaluation of angiostatic steroids to prevent scarring in eyes with advanced glaucoma requiring repeated filtration surgery. Alcon Laboratories, principal investigator.
- 1996-1998 The evaluation of Short Wave Length Automated Perimetry in Normal and Glaucoma Eyes. Humphrey Systems.
- 1996-1998 The evaluation of SITA threshold algorithm in perimetry. Humphrey Systems.
- 1997-1998 A comparison of Humphrey threshold to Dicon perimetric evaluations. Humphrey Systems.

- 1998-2001 A six-month, triple-masked, parallel group, primary therapy study of the safety and efficacy of AL - 6221 0.0015% and AL- 6221 0.004% compared to timoptic 0.5% in patients with open angle glaucoma or ocular hypertension. Alcon Laboratories
- 1998-1999 A prospective comparison of diode cyclophotocoagulation and trabeculectomy in eyes with primary open angle glaucoma prior to other surgical intervention. Iris Medical, principal investigator
- 2000-2003 Evaluation of Oculus Perimeter and Humphrey Perimetry: a comparison. Chief Investigator
- 2001-2005 Evaluation of GDX for early detection of glaucoma. Chief investigator.
- 05/01/09-04/30/14 R01 EY018400-01A. Communication about Glaucoma and Patient Outcomes. Sleath (PI) (subcontractor)
- 5/1/12-4/30/13 R34 Clinical Trial Planning Grant. Title: [Statins to Prevent Progression of Glaucoma: The STOP Glaucoma Trial \(clinical site, 10% of time\)](#)

XII. PATENTS, INVENTIONS, AND COPYRIGHTS

20060173437 - Surgical Method August 3, 2006

An irrigating technique that can be used to increase the flow of fluid through the trabecular meshwork. Pulses of relatively high pressure irrigating are directed at the trabecular meshwork. These pulses can be focused, thereby perforating the trabecular meshwork, or applied over a larger area so as to stimulate the trabecular meshwork for improved fluid transport. In addition, the pulses of the irrigating balance salt solution can be used to clean away material, such as iris pigment, that may be blocking or clogging the trabecular meshwork. Such a technique may be practiced using the herein disclosed tip with commercially available surgical handpieces.

XIII. PUBLICATIONS

Peer-reviewed journal articles

1-**Robin AL**, Green WR, Lapsa TP, Hoover RE, Kelley JS. Recurrence of macular corneal dystrophy after lamellar keratoplasty. *Am J Ophthalmol* 84;1977:457-461.

2-Kelley JS, Hoover RE, **Robin AL**, Kincaid M. Laser scotometry in drusen and pits of the optic nerve head. *Ophthalmology* 86;1979:442-447.

3-**Robin AL**, Quigley HA. Transient reversible cupping in juvenile glaucoma. *Am J Ophthalmol* 88;1979:580-584.

4-**Robin AL**, Quigley HA, Pollack IP, Maumenee AE, Maumenee IH An analysis of visual acuity, visual fields, and disk cupping in childhood glaucoma. *Am J Ophthalmol*. 1979 Nov;88(5):847-58.

5-Pollack IP, **Robin AL***#. Iridotomies in cynomolgus monkeys using a Q-switched ruby laser. *Trans Am Ophthalmol Soc*. 78;1980:88-103.

6-Hirst LW, **Robin AL**, Sherman S, Green WR, D'Anna S, Dunkelberger G. Corneal endothelial changes after argon laser iridotomy and panretinal photocoagulation. *Am J Ophthalmol* 93;1982:473-481.

7-**Robin AL***#, Pollack IP. Argon laser peripheral iridotomies in the treatment of primary angle-closure glaucoma: Long-term follow-up. *Arch Ophthalmol* 100;1982:919-923.

8-Pollack IP, **Robin AL**. Argon laser trabeculoplasty: Its effect on medical control of glaucoma following argon laser trabeculoplasty. *Ophthalmic Surgery* 13;1982:637-643.

9-**Robin AL**, Pollack IP, Quigley HA, D'Anna S, Addicks EM: Histologic studies of angle structures after laser iridotomy in primates. *Arch Ophthalmol* 100;1982:1665-1670.

11-**Robin AL***#, Pollack IP: Argon laser trabeculoplasty in secondary forms of open-angle glaucoma. *Arch Ophthalmol* 101;1983:382-384.

12-Addicks EM, Quigley HA, Green WR, **Robin AL**: Histologic characteristics of filtering blebs in glaucomatous eyes. *Arch Ophthalmol* 101;1983:795-799.

13-Pollack IP, **Robin AL**#, Sax H: The effect of argon laser trabeculoplasty on the medical control of primary open-angle glaucoma. *Ophthalmology* 90;1983:785-789.

14-Hotchkiss ML, **Robin AL**#, Pollack IP, Quigley HA: Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty: A trial with flurbiprofen and indomethacin. *Ophthalmology* 91;1984:969-974.

15-**Robin AL***#, Pollack IP: The Q-switched ruby laser in glaucoma. *Ophthalmology* 91;1984:366-372.

16-**Robin AL**, Pollack IP: Argon laser trabeculoplasty in the secondary glaucomas. *ACTA International Congress of Ophthalmology XXIV*;1983:620-628.

17-Safran M, **Robin AL**#, Pollack IP: Argon laser trabeculoplasty in younger patients with primary open-angle glaucoma. *Am J Ophthalmol* 97;1984:292-

295.

18-Weinreb R, **Robin AL**, Brevardt G, Drake M, Blumenthal M, Wilensky J: Flurbiprofen pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma. *Arch Ophthalmol* 102;1984:1629-1632.

19-**Robin AL**#, Pollack IP: A comparison of neodymium:YAG and argon laser iridotomies. *Ophthalmology* 91;1984:1011-1016.

20-Gilbert CM, **Robin AL**#, Pollack IP: Hyphema complicating neodymium:YAG iridotomy. *Ophthalmology* 91;1984:1123

21-Sommer A, Kues HA, D'Anna SA, Arkell S, **Robin AL**, Quigley HA: Cross-polarization photographs of the nerve fiber layer. *Arch Ophthalmol* 102;1984:864-869.

22-Sommer A, Quigley HA, **Robin AL**, Miller N, Katz J, Arkell S: Evaluation of nerve fiber layer assessment. *Arch Ophthalmol* 102;1984:1766-1771.

23-Flohr M, **Robin AL**#, Kelley JS: Early complications following Q-switched neodymium:YAG posterior capsulotomy. *Ophthalmology* 92;1985:360-363.

24-Pollack IP, **Robin AL**#, Dragon DM, Green WR, Quigley HA, Murray TG and Hotchkiss ML: Use of the neodymium:YAG laser to create iridotomies in monkeys and humans. *Trans Am Ophthalmol Soc* 82;1984:307-328.

25-Hotchkiss ML, **Robin AL**#, Quigley HA, Pollack IP: A comparison of Peritest automated and Goldmann perimetry. *Arch Ophthalmol* 103;1985:397-403.

26-Dragon DM, **Robin AL**#, Pollack IP, Quigley HA, Green WR, Murray TG, Hotchkiss ML, and D'Anna S: Neodymium:YAG laser iridotomy in the cynomolgus monkey. *Invest Ophthalmol Vis Sci* 26;1985:789-796.

27-Gross JG, **Robin AL**: Argon laser iridocorneal adhesiolysis. *Am J Ophthalmol* 100;1985:330-331.

28-**Robin AL**, Pollack IP: Q-switched neodymium-YAG laser angle surgery in open-angle glaucoma. *Arch Ophthalmol* 103;1985:793-795.

29-**Robin AL**: Intraocular pressure elevation following anterior segment laser surgery. *Ophthalmic Laser Therapy* 1;1986:101-106.

30-**Robin AL***, Pollack IP: Q-switched neodymium:YAG laser iridotomy in patients where the argon laser fails. *Arch Ophthalmol* 104;1986:531-535.

- 31-**Robin AL***, Arkell S, Gilbert SM, Goossen AA, Werner RP, Korshin OM: Q-switched neodymium-YAG laser iridotomy. A field trial with a portable laser system. *Arch Ophthalmol* 104;1986: 526-530.
- 32-Hotchkiss ML, Quigley HA, Green WR, Pollack IP, **Robin AL**: The effect of laser capsulotomy on aqueous humor dynamics in the monkey eye. *Ophthalmology* 93;1986:1270-1275.
- 33-**Robin AL**: Intraocular pressure rise after iridotomy. *Arch Ophthalmol* 104;1986:1117.
- 34-Burney EN, Quigley HA, **Robin AL**: Hypotony and choroidal detachment as late complications of trabeculectomy. *Am J Ophthalmol* 1987;103:685-688.
- 35-**Robin AL**, Pollack IP, House B, Enger C: Effect of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. *Arch Ophthalmol* 1987;105:646-650.
- 36- Lynch MG, Quigley HA, Green WR, Pollack IP, **Robin AL**. The effect of neodymium: YAG laser capsulotomy on aqueous humor dynamics in the monkey eye. *Ophthalmology* 1986;93:1270-5.
- 37-**Robin AL**, Pollack IP, DeFaller JM: Effects of topical ALO 2145 (p-Aminoclonidine Hydrochloride) on intraocular pressure rise following argon laser iridotomy. *Arch Ophthalmol* 1987;105:1208-1211.
- 38-Abrams DA, **Robin AL**#, Pollack IP, DeFaller J, DeSantis L: An evaluation of the safety and efficacy of topical 1% ALO 2145 (p-Aminoclonidine Hydrochloride) in normal patients. *Arch Ophthalmol* 1987;105:1205-1207.
- 39-**Robin AL**: Advantages of a portable Q-switched neodymium-YAG laser system for anterior segment surgery. *Arch Ophthalmol* 1987;105:892.
- 40-**Robin AL***, Pollack IP, House B, Enger C: Medical therapy for the acute postoperative intraocular pressure rise following argon laser trabeculoplasty. *Arch Ophthalmol* 1987;105:1476-7.
- 41-Long D, Allen RC, **Robin AL**, David R, Ober R, Sharrer A, Massi R, Elman J, Lue JC, Novack GD: Levobunolol concomitant treatment with dipivefrin or pilocarpine for glaucoma therapy. *New Trends in Ophthalmology* 1987;2:66-70.
- 42-Del Priore LV, **Robin AL**#, Pollack IP. Long-term follow-up of neodymium:YAG laser angle surgery for open-angle glaucoma. *Ophthalmology* 1988;95:277-281.

- 43-Pollack IP, Brown RH, Crandell AS, **Robin AL**, Stewart RH, White GL. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% ALO 2145. *Arch Ophthalmol* 1988;106:754-757.
- 44-**Robin AL**#, Pollack IP, DeFaller JM. Effects of topical ALO 2145 (p-Aminoclonidine Hydrochloride, Aplonidine Hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. *Arch Ophthalmol* 1988;106:308-309.
- 45-Del Priore LV, **Robin AL**#, Pollack IP. Neodymium:YAG and argon laser iridotomy: Long-term follow-up in a prospective clinical trial. *Ophthalmology* 1988;95:1207-1211.
- 46-**Robin AL**. Separating the wheat from the chaff. *Ophthalmic Surgery* 1988;19:292.
- 47-**Robin AL**. Short-term effects of unilateral 1% apraclonidine therapy. *Arch Ophthalmol* 1988;106:912-915.
- 48-Gross JG, Meyer DR, **Robin AL**#, Filar AA, Kelley JS. Increased intraocular pressure in the immediate postoperative period after extracapsular cataract extraction. *Am J Ophthalmol* 1988;105:466-469.
- 49-Blumenthal M, **Robin AL**, Ritch R, Baerveldt G, Wilensky J, Cheetham JK. Flurbiprofen administered topically to secondary glaucoma patients undergoing argon laser Trabeculoplasty. *Ophthalmic Laser Therapy* 1987;2:249-257.
- 50-Jampel HD, **Robin AL**#, Quigley HA, Pollack IP. Apraclonidine Hydrochloride: A one-week dose-response study. *Arch Ophthalmol* 1988;106:1069-1073.
- 51-Allen RC, **Robin AL**, Long D, Novack GD, Lue JC, and Kaplan G: A combination of levobunolol and dipivefrin for the treatment of glaucoma. *Arch Ophthalmol* 1988;106:904-907.
- 52-Javitt JC, **Robin AL**#, Pollack IP. Uses of the neodymium:YAG laser in the treatment of open angle glaucoma. *Ophthalmology Clinics of North America* 1988;1:265-275.
- 53-Morrison JC, **Robin AL**. Adjunctive glaucoma therapy: a comparison of apraclonidine and dipivefrin when added to timolol maleate. *Ophthalmology* 1989;96:3-7.
- 54-Pollack IP, Brown RH, Crandall AS, **Robin AL**#, Stewart RH, White GL. Effectiveness of apraclonidine in preventing the rise in intraocular pressure

after neodymium:YAG posterior capsulotomy. *Trans Am Ophthalmol Soc* 1988;86:461-472.

55-Abrams DA, **Robin AL**#, Crandell AS, Caldwell DR, Schnitzer DB, Pollack IP, Rader JE, Reaves TA Jr. A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure *Am J Ophthalmol* 1989;108:230-237.

56-Colemann AL, **Robin AL**#, Pollack IP. Apraclonidine Hydrochloride. *Ophthalmology Clinics of North America* 1989;2:97-108.

57-Dandona L, Morrison JC, **Robin AL**, Quigley HA. Role of "outliers" in statistical analysis involving intraocular pressure readings. *Ophthalmic Surg* 1989;20:737-743.

58-**Robin AL**. The role of apraclonidine hydrochloride in laser therapy for glaucoma *Trans Am Ophthalmol Soc* 1989;87:729-761.

59-**Robin AL**. Acute postoperative intraocular pressure rises associated with anterior segment ophthalmic laser surgery and their medical management. *Int Ophthalmol Clinics* 1990;30:102-110.

60-**Robin AL**. Apraclonidine uses. *Arch Ophthalmol* 1990;108:337.

61-Coleman AL, **Robin AL**#, Pollack IP, Rudikoff MT, Enger C, Mayer PR: Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine hydrochloride *Arch Ophthalmol* 1990;108:1264-1267.

62-**Robin AL**. Argon laser trabeculoplasty: medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty. *Ophthalmic Surg* 1991;22:31-37.

63-Hurvitz LM, Kaufman PL, **Robin AL**, Weinreb RN, Crawford K, Shaw B. New Developments in the drug treatment of glaucoma. *Adis (Drugs)* 1991;41:514-532.

64-**Robin AL***#, Coleman AL. Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate *Trans Am Ophthalmol Soc*, 1990;87:149-162.

65-Diehl DLC, **Robin AL**, Wand M: The influence of iris pigmentation on the miotic effect of thymoxamine. *Am J Ophthalmol* 1991;111:351-355.

66-Sommer A, Katz J, Quigley HA, Miller NR, **Robin AL**, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of

glaucomatous field loss. *Arch Ophthalmol* 1991;109:77-83.

67- Sulewski ME, **Robin AL#**, Cummings HL, Arkin LM. Effects of topical flurbiprofen on the intraocular pressure lowering of apraclonidine hydrochloride and timolol maleate. *Arch Ophthalmol*, 1991;109:807-809.

68-Ruit S, **Robin AL#**, Pokhrel RP, Sharma A, DeFaller J. Extracapsular cataract extraction in Nepal: 2-year outcome. *Arch Ophthalmol*, 1991;109:1761-1763.

69-Ruit S, **Robin AL#**, Pokhrel RP, Sharma A, DeFaller J, Maguire PT. Long-term results of extracapsular cataract extraction and posterior chamber intraocular lens insertion in Nepal. *Trans Am Ophthalmol Soc*, 1991;89:59-76.

70-**Robin AL**. Medical therapy to prevent intraocular pressure rise associated with argon laser trabeculoplasty. *Ophthalmology Digest* 1: 12, 1991.

71-Vocci MJ, **Robin AL#**, Wahl JC, Mayer P, Graves A, York B, Sutton J, Enger C. Reformulation and drop size of apraclonidine hydrochloride. *Am J Ophthalmol*, 1992;113:154-160.

72-Derick RJ, **Robin AL#**, Tielsch J, Wexler JL, Kelley EP, Stoecker JF, Novack GD, Coleman AL. Once-Daily versus twice-daily levobunolol (0.5%) therapy: A crossover study. *Ophthalmology*, 1992;99:424-429.

73- Ruit S, **Robin AL#**, Pokhrel RP, Sharma A, DeFaller J. In reply: Lewallen S, LeMeasurier RT. Extracapsular extraction in developing countries. *Arch Ophthalmol*, 1993;111:18-19.

74-Cioffi GA, **Robin AL#**, Eastman RD, Perell HF, Sarfarazi FA, Kelman SE. Reproducibility of Optic Nerve Head Topographic Measurements with the Confocal Laser Scan Ophthalmoscope. *Ophthalmology*, 1993;100:57-62.

75-Ritch R, Liebman J, **Robin A**, Pollack IP, Harrison R, Levene RZ, Hagadus J. Argon laser trabeculoplasty in Pigmentary Glaucoma. *Arch Ophthalmol* 1993;100:909-913.

76-Ramakrishnan R, Michon J, Natchiar G, **Robin AL**. Bilateral extensive persistent pupillary membranes treated with the Nd:YAG laser. *Arch Ophthalmol*, 1993;111:28.

77-**Robin AL**. Pitfalls in comparing the costs of various alpha-adrenergic antagonists. *Arch Ophthalmol* 1993;111:299.

78-Natchiar G, **Robin AL#**, Nalgirkar AR, Krishnadas, R. Posterior Capsule Tears during Extracapsular Cataract Surgery in India. *Arch Ophthalmol* 1993;111:706-708.

79-**Robin AL**. Effect of topical apraclonidine on the frequency of intraocular pressure elevations following combined extracapsular cataract extraction and trabeculectomy. *Ophthalmology* 1993;100:628-633.

80-Barnebey HS, **Robin AL**, Zimmerman TJ, Morrison JC, Hersh SB, Lewis RA, Coleman AL, Cinotti DJ, Walt J, Chen KS, Kelley EP. The Efficacy of Brimonidine in Decreasing Elevations in Intraocular Pressure after Laser Trabeculectomy. *Ophthalmology* 1993;100:1083-1088.

81-Ramakrishnan R, Michon J, **Robin AL#**, R Krishnadas. Safety and Efficacy of Mitomycin C Trabeculectomy in Southern India: A Short-Term Pilot Study. *Ophthalmology*, 1993;100:1619-1623.

82-**Robin AL**. In discussion of: Rait JL, Kolker AE, Kass, MA. Releasable Sutures for Trabeculectomy. *Trans Am Ophthalmol Soc.* 1993;91:141-144.

83-Novack GD, **ROBIN AL**, Derick RJ. New Medical Treatments for Glaucoma. *Int Ophthalmol Clinics*, 1993;33:183-202.

84-Schwartz GF, **Robin AL#**, Wilson RP, Suan EP, Pheasant TR, Prensky JG. Suturing the scleral flap leads to resolution of hypotony maculopathy. *J Glaucoma* 1996;5:246-251.

85-Novack GD, **Robin AL**. Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice? *Arch Ophthalmol*, [letter to the editor] 1994;112:726.

86-**Robin AL**, Ritch R, Shin D, Smythe B, Mundorf T, Lehmann RP, The Apraclonidine Study Group.432. The Short-Term Efficacy of Apraclonidine Hydrochloride when Maximum Tolerated Medical Therapy Fails to Control Intraocular Pressure. *Am J Ophthalmology* 1995;120:423.

87-Natchiar G, **Robin AL#**, Thulasiraj RD, Ravilla D, Krishnaswamy S. Attacking the Backlog of India's Curable Blind: The Aravind Eye Hospital Model. *Arch Ophthalmol*,1994;112:987-993.

88-Nordlund JR, Pasquale LR, **Robin AL#**, Rudikoff MT, Ordman J, Chen KS, Walt J. The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of Brimonidine Tartrate 0.2%. *Arch Ophthalmol*,1995;113:77-83.

89- **Robin AL**. Questions Concerning the Role of Apraclonidine in the Management of Glaucoma [Editorial]. *Arch Ophthalmol* 1995;113: 712-715.

90- Camras CB and the USA Latanoprost Study Group. Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma--Six-Month, Masked USA Multicenter Trial. *Ophthalmology*. 1996;103:138-

147.

91-**Robin AL**:Apraclonidine Hydrochloride: Its Past, Present, and Future in the Therapy of Chronic Glaucoma. *J Glaucoma*,1995;4 (Supplement): 24-30.

92-The Brimonidine-ALT Study Group: Effect of Brimonidine 0.5% on Intraocular Pressure Spikes Following 360^N Argon Laser Trabeculoplasty. *Ophthalmic Surgery and Lasers*. 1995;26:404-409.

93- **Robin AL**, Natchiar M, Thulasiraj RD, Venkataswamy G. A Long-Term Approach to World Wide Cataract Blindness . *Editorial. Ophthalmology* 1997;104:571-572.

94-**Robin AL**, Barneby HS, Choplin N, Lewis R, Walters TR, Epstein D, Zimmerman T, van Buskirk EM, Cyrlin M, David R, Batoosingh A, Walt J. Brimonidine tartrate dose-response study in glaucoma and ocular hypertension. *Eur J Ophthalmol* 1995;5 (Suppl): 156.

95-**Robin AL**, Ritch R, Shin D, Smythe B, Mudnforf T, Lehmann RP, The Apraclonidine Maximal Tolerated Medical Therapy Study Group. Topical Apraclonidine Hydrochloride in Eyes with Poorly Controlled Glaucoma. *Trans Am Ophthalmol Soc* 1995;93:421-441.

96-Derick RJ, **Robin AL**, Walters TR, Barneby HS, Choplin N, Kelley EP, Stoecker JF. Brimonidine Tartrate: A One Month Dose Response Study. *Ophthalmology*, 1997;104:131-136.

97-Camras CB, Alm A, Watson P, Stjernschantz J, The Latanoprost Study Groups: Latanoprost, a Prostaglandin Analog, for Glaucoma Therapy: Efficacy and Safety After One Year of Treatment in 198 Patients. *Ophthalmology*,1996;103:1916-1924.

98-Camras Carl B and the United States Latanoprost Study Group. Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma: A Six-Month, Masked, Multicenter Trial in the United States. *Ophthalmology*: 1996;103:138.

99-**Robin AL**. Ocular Hypotensive Efficacy and Safety of A Combined Formulation of Betaxolol and Pilocarpine. *Trans Am Ophthalmol Soc*, 1996;94:89-103.

100-**Robin AL**, Smith SD, Natchiar G, Ramakrishnan R, Srinivasan M, Hecht W. The Initial Complication Rate of Phacoemulsification in India. *Investigative Ophthalmology and Visual Sciences*, 1997; 38:2331-2337.

101-Serle JB, The Brimonidine Study Group III. A Comparison of the Safety

and Efficacy of Twice Daily Brimonidine 0.2% Versus Betaxolol 0.25% in Subjects with Elevated Intraocular Pressure. *Surv Ophthalmol* 1996;41 [Suppl 1]S39-47.

102-**Robin AL**. The role of alpha-agonists in glaucoma. *Curr Opin Ophthalmol* 1997;8:42-49.

103- **Robin AL**. The role of alpha-agonists in glaucoma therapy. *Curr Opin Ophthalmol* 1997;8(2):42-9.

104-**Robin AL**, Ramakrishnan R, Krishnadas R, Smith SD, Katz JD, Selvaraj S, Skuta GL, Bhatnagar R. A Long-Term Dose Response Study of Mitomycin C in Glaucoma Filtration Surgery. *Arch Ophthalmol*, 1997;115:969-974.

105-**Robin AL**. Decreasing Blindness in Developing Countries. *Ophthalmology* 1998;105:569.

106- Derick RJ, **Robin AL**, Walters TR, Barnabey HS, Choplin N, Schuman J, Kelley EP, Chen K, Stoecker JF. Brinomidine and pupillary diameter: Authors' reply. *Ophthalmology* 1998;105(8):1352-1353.

107- Camras CB, Wax MB, Ritch R, Weinreb R, **Robin AL**, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T, Stjernschantz J. . Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. *Am J Ophthalmol*. 1998;126(3):390-9.

108- **Robin AL**, Burnstein Y. Selectivity of site of action and systemic effects of topical alpha agonists. *Curr Opin Ophthalmol*, 1998 Apr;9(2):30-3.

109-Shingleton BJ, Crandall A, **Robin A**, Brown R. Medical treatment patterns of ASCRS members for primary open-angle glaucoma-1998 survey. *J Cataract Refract Surg* 1999;25:118-127.

110- Burnstein Y, **Robin AL**. Pressure or progression. *Arch Ophthalmol*; 1999;117(3):417-9.

111-**Robin AL**. Estimation of Cataract Blindness In India. *Ophthalmology* 1999;106:5-6.

112- **Robin AL**. The Madurai IOL Study I-III. *Am J Ophthalmol*. 1999;127(1):110-11.

113-Gordon M., Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants. *Arch Ophthalmol* 1999;117:573-583.

114-Åsman, P, Fingeret M, **Robin AL**, Wild J, Pacey I, Greenfield D, Liebman J, Ritch R. Kinetic and Static Fixation Methods in Automated Threshold Perimetry. *Journal of Glaucoma* 1999;8:290-296.

115-Patel S., Friedman DR, ; Parna; **Robin AL**. Algorithm for Interpreting the Results of Frequency Doubling Perimetry. *Am J Ophthalmol* ,2000;129:323-327.

116-Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO, Ocular Hypertension Treatment Study Group. Contralateral Effect of Topical alpha-Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2000; 130:441-453.

117-Camras Carl B and the United States Latanoprost Study Group. Latanoprost Treatment for Glaucoma: Effects of Treating for One Year and of Switching from Timolol. *Am J American Journal of Ophthalmology*, 1998;126:390-399.

118-Altuna JC, Greenfield DS, Wand M, Liebmann JM, Camras C, Kaufman P, Cioffi GA, Lee DA, **Robin AL**, Crichton A, Costa V, Ritch R. Latanoprost in Glaucoma Associated With Sturge-Weber Syndrome: Benefits and Side-Effects. *J Glaucoma*. 1999 Jun;8(3):199-203.

119-Jampel HD, Quigley HA, Kerrigan-Baumrind LA, Melia M, Friedman D, Barron Y, Glaucoma Surgical Outcomes Study Group. *Arch Ophthalmol*. 2001.119:1001-1008.

120-Krishnadas R, Nirmalan PK, Ramakrishnan R, Thulasiraj RD, Katz J, Tielsch JM, **Robin AL**. Pseudoexfoliation in a rural population of southern India: The Aravind Comprehensive Eye Survey. *Am J Ophthalmol* 2003; 135: 830-837.

121-Ramakrishnan R, Nirmalan PK, Krishnadas R Thulasiraj RD, Tielsch JM, Katz J, **Robin AL**. Glaucoma in a rural population of southern India: The Aravind Comprehensive Eye Survey. *Ophthalmology*, 2003;110:1484-1490.

122-R Thulasiraj RD, Nirmalan PK, Ramakrishnan R, Krishnadas, Tielsch JM, Katz J, **Robin AL**. Blindness and vision impairment in a rural population of southern India: The Aravind Comprehensive Eye Survey. *Ophthalmology*, 2003;110:1491-1498.

123- Halpern MT, Covert DW, **Robin AL**..Projected Impact Of Travoprost Versus Both Timolol and Latanoprost On Visual Field Deficit Progression And Costs Among Black Glaucoma Subjects. *Trans Amn Ophthal Soc.*2002;100:

33-42.

124-Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents The Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol* 2002; 120:701-713.

125-Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Chohnso CA, Keltner JL, Miller JP, Parrish RK, Wilson, MR, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol.* 2002;120:714-720.

126-**Robin AL**, Frick KD, Katz J, Tielsch JM. The Ocular Hypertension Treatment Study. IOP Lowering Prevents The Development of Glaucoma, But Does That Mean We Should Treat Before The Onset of Disease. *Arch Ophthalmol*, 2004; 122:376-377.

127-Jampel HD. Schwartz GF, **Robin AL**, Abrams D, Johnson E, Miller RB: Patient preferences for eyedrop characteristics: A Willingness to pay Analysis. *Arch Ophthalmol.* 2003;121: 540-546.

128- **Robin AL**. An accurate comparison of bimatoprost's efficacy and adverse effects. Letter To The Editor. *Arch Ophthalmol* 2002;120:999-1000.

129-**Robin, AL**. A Six Month Randomized Clinical Trial Comparing the IOP Lowering Efficacy of Bimatoprost and Latanoprost in Patients With Ocular Hypertension Or Glaucoma. Letter To The Editor . *Am J. Ophthalmology* 2003;135:921-922.

130-Nirmalan PK, Krishnadas R, Ramakrishnan R, Thusasiraj RD, Katz J, Tielsch JM, **Robin AL**. Lens opacities in a rural population of southern India. *Invest Ophthalmol Vis Sci*, 2003;44:4639-4643.

131-Hylton C, **Robin AL**. Update on prostaglandin analogs. *Current Opinion in Ophthalmology* 2003;14(2): 65-9.

132-Camras CB, Hedman K, US Latanoprost Study Group. Rate of Response to Latanoprost or Timolol in Patients With Ocular Hypertension or Glaucoma. *J Glaucoma* 2003;12:466-9.

133-Nirmalan PK, Thusasiraj RD, Krishnadas R, Ramakrishnan R, Katz J,

Tielsch JM, **Robin AL**. Lens disorders in a rural population of southern India. II. Risk factors for age-related cataract. The Aravind Comprehensive Eye Study. *Br J Ophthalmol*. 2004;88:989-994.

134-Jampel HD, Parekh P, Johnson E, **Robin AL**, Miller RB. Preferences for eye drop characteristics among glaucoma specialists: A willingness-to-pay analysis. *J Glaucoma*. 2005;14:151-156.

135-Nirmalan, PK, Katz J, **Robin AL**#, Tielsch JM, Namperumalsamy P, Kim R, Narendran V, Ramakrishnan R, Krishnadas R, Thulasiraj RD, Suan E. Prevalence of vitreo-retinal disorders in a rural population of southern India: The Aravind Comprehensive Eye Study. *Arch Ophthalmology*, 2004;122:581-586.

136-**Robin AL**, Katz J, Tielsch JM, Friedman DS, Ramakrishnan R, Krishnadas R, Thulasiraj RD. Letter to the Editor: Glaucoma in southern India. *Ophthalmology* 2004; 111: 846-847.

137-Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA, The OHTS CLSO Ancillary Study Group. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study Design and Baseline Factors. *Am J Ophthalmol* 2004; 137:219-227.

138-Nirmalan PK, Katz J, Tielsch JM, **Robin AL**#, Thulasiraj RD, Krishnadas R, Ramakrishnan R. Ocular trauma in a rural south Indian population: The Aravind Comprehensive Eye Study. *Ophthalmology*, 2004;111:1778-1781.

139-Nirmalan PK, **Robin AL**#, Katz J, Tielsch JM, Thulasiraj RD, Krishnadas R, Ramakrishnan R. Risk factors for age related cataract in a rural population of southern India: The Aravind Comprehensive Eye Study. *Br J Ophthalmol*. 2004;88:989-994.

140-Nirmalan PK, **Robin, AL**. Indicators to evaluate success of eye care programs. *Ophthalmologia*. 2004;16:15-18.

141-Nirmalan PK, Katz J, **Robin AL**#, Krishnadas R, Ramakrishnan R, Thulasiraj RD, Tielsch J. Utilization of eye care services in rural south India: The Aravind Comprehensive Eye Survey (ACES). *Br J Ophthalmol*, 2004;88:1237-1241.

142-Nirmalan PK, Katz J, **Robin AL**#, Ramakrishnan R, Krishnadas R, Thulasiraj RD, Tielsch J. Female Reproductive Factors and Eye Diseases in a

Rural South Indian Population: The Aravind Comprehensive Eye Survey. *Invest Ophthalmol Vis Sci* 2004;45:4273-4276.

143-**Robin AL***, Nirmalan PK, Krishnadas R, Ramakrishnan R, Katz J, Tielsch J, Thulasiraj RD. The utilization of eye care services by persons with glaucoma in rural south India. *Trans Am Ophthalmol Soc*, 2004; 47-56.

144-Brandt JD, Beiser JA, Gordon MO, Kass, MA, Ocular Hypertension Treatment Study (OHTS) Group. Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypertensive Medication in the Ocular Hypertension Treatment Study. *Am J Ophthalmol*, 2004 Nov;138(5):717-22.

145-**Robin AL***, Covert D. Does Adjunctive Glaucoma Therapy Affect Adherence to the Initial Primary Therapy? *Ophthalmology*2005;112:863-868.

146-**Robin AL***, Nirmalan PK, Krishnadas R, Ramakrishnan R, Katz J, Tielsch J, Thulasiraj RD, Friedman DS. The Utilization of Eye Care Services By Persons With Glaucoma in Rural South India. *Trans Am Ophthalmol Soc* 2004;102:47-55.

147-Nirmalan PK, Tielsch JM, Katz J, Thulasiraj RD, Krishnadas R, Ramakrishnan R, **Robin AL**. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. *Invest Ophthalmol Vis Sci*. *Invest Ophthalmol Vis Sci*. 2005 Jul;46(7):2308-12.

148-Covert D, **Robin AL**#, Novack G. [letter to the editor] Systemic Medications and Glaucoma Patients. *Ophthalmology*. 2005;120:1849.

149-Tsai T, **Robin AL**#, Smith JP3rd. An Evaluation of how Glaucoma Patients use topical medications: A Pilot Study. *Trans Am Ophthalmol Soc*. 2007;105:29-33; discussion 33-5.

150-Sleath B, **Robin AL**#, D D, Byrd JE, Tudor G, Svarstad B. Patient-reported problems and behavior in using glaucoma medications *Ophthalmology*, 2006;113:436-441. PMID: 16458967

151-Covert D, **Robin AL**. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. *Current Medical Research and Opinion*, 2006;22:971-976.

152-Dorairaj SK, **Robin A**, Shihadeh W, Greenberg S, Liebmann JM, Ritch R. Phenotypic variability of Pigment Dispersion Syndrome in Children. *Archives*

of Ophthalmology, 2007;125:136-138.

153-**Robin AL**. Comments on paper: A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. *European Journal of Ophthalmology* 2007; 17: 4067– 4068.

154-Ramulu PY, Corcoran KJ, Corcoran SL, **Robin AL**. Utilization of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1995 to 2004., *Ophthalmology* 2007;114:2265-2270.

155-Schmier JK, Halpern MT, Covert DW, **Robin, AL**. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. *Cuirrent Medical Research and Opinions*. 2006;22:1737-1743.

156-Schmier JK, Halpern MT, Covert DW, Lau EC, **Robin AL**. Evaluation of Medicare Costs of Endophthalmitis among Patients Following Cataract Surgery. *Ophthalmology*, 2007;114:1094-1099.

157-**Robin AL***, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence In Glaucoma: Objective Measurements of Once-daily and Adjunctive Medication Use. *Am J Ophthalmol*. 2007;144:533-540.

158-Sleath B, Byrd JE, **Robin AL**, Covert DW, Tudor G. Glaucoma Patient Receipt of Information and Instruction on how to use their eye drops. *International Journal of Pharmacy Practice*. 2008; 16:35-40.

159-Schmier JK, Covert DW, **Robin A**: Estimated first-year costs of prostaglandin analogues with/without adjunctive therapy for glaucoma management: A United States perspective. *Current Medical Research and Opinions*. 2007;23(11):2867-2875.

160-Whitson JT, Roarty JD, Vijaya L, **Robin AL**, Gross RD, Landry TA, Dickerson JE, Scheib SA, Scott H, Hua SY, Woodside AM, Bergamini MVW. Efficacy of Brinzolamide and Levobetaxolol in Pediatric Glaucomas: A Randomized Pediatric Trial. *J Am Assoc Ped Ophthalmic Surgeons*. 2008;12:239-246.

161-Lee BW, Parthasarathi S, John RK, Singh K, **Robin AL**. Predictors of and Barriers Associated with Poor Follow-up among Glaucoma Patients in South India. *Archives of Ophthalmology* 2008;126:1448-1454.

162-Aptel F, Masset H, Burillon C, **Robin A**, Denis P. The influence of

quality of eye drop administration in patients with glaucoma or ocular hypertension. *British J of Ophthalmol*, 2009;93:700-701.

163-Sleath BL, Krishnadas R, Cho M, **Robin AL**, Mehta R, Covert D, Tudor G. Patient Reported barriers to glaucoma medication access, use, and adherence in Southern India. *Indian Journal of Ophthalmology*, 2008;57:63-68. PMID: 19075417

164-**Robin AL***, Clark AF, Covert DW, Krueger S, Bergamini MVW, Landry TA, Dickerson JE, Scheib SA, Realini T, Defaller JM, Cagle GD. Anterior Juxtasceral Delivery of Anecortave Acetate In Eyes With Primary Open-Angle Glaucoma: A Pilot Investigation. *Am J Ophthalmol*, 2009;147:45-50.

165-**Robin AL***, Suan EP, Sjaarda RN, Callanan DG, DeFaller JD, Alcon Anecortave Acetate For IOP Research Team. Anecortave Acetate Lowers Intraocular Pressure in Eyes With Steroid-Related Ocular Hypertension. *Archives of Ophthalmology*. 2009;127:173-178.

166-Stone JL, **Robin AL**#, Novack GD, Covert DW, Cagle GD. An Objective Evaluation of Eye-Drop Instillation in Glaucoma Patients. *Archives of Ophthalmology*, 2009;127:732-736.

167-Schmier JK, Covert DW, Lau EC, **Robin AL**. Trends in Annual Medicare Expenditures for Glaucoma Surgical Procedures from 1997 – 2006. *Archives of Ophthalmology*, 2009;127:900-905.

168-Iskedjian M, Walker JH, Desjardins O, **Robin AL**, Covert DW, Bergamini MV, Einarson TR. Effect of Selected Antihypertensives, Antidiabetics, Statins, and Diuretics on Adjunctive Medical Treatment of Glaucoma: A Population Based Study. *Curr Med Res. Opin.* 2009; 25:1879-88.

169-Schmier JK, Covert DW, **Robin AL**. First-Year Treatment Patterns Among New Initiators of Topical Prostaglandin Analogues. *Current Medical Research and Opinion*. 2009; 25: 851-858.

170-Sleath B, Ballinger R, Covert D, Robin AL, Byrd JE, Tudor G. Veteran race, mail order use, glaucoma medication problems, and adherence. *Am J Geriatric Pharmacotherapy*. 2009;7(2):62-73. PMID: 19447359.

171- Plager DA, Whitson JT, Netland PA, Vijaya, L, Sathyan P, Sood D, Krishnadas SR, **Robin AL**, Gross RD, Scheib SA, Scott H, Dickerson JE, and the BETOPTIC(r) S Pediatric Study Group. Efficacy and Safety of Betaxolol Hydrochloride Ophthalmic Suspension 0.25% and Timolol Gel Forming

Solution 0.25% and 0.5% in Pediatric Glaucoma: A Randomized Clinical Trial. *Journal of the American Association for Pediatric Ophthalmology and Strabismus*. 2009;13:384-390.

172-Sleath B, Blalock SJ, **Robin AL**, Hartnett MEM, Covert D, Devellis B, Giangiaco A. Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. *Eye*. 2009, 1-8. PMID: 19648896

173-Schmier JK, Covert DW, **Robin AL**. First-Year Treatment Costs Among New Initiators of Topical Prostaglandin Analog Identified From November 2007 Through April 2008. *Current Medical Research and Opinion*. 2011;26:2769-77.

174-Schmier JK, Covert DW, **Robin AL**: First-Year Treatment Costs Among New Initiators of Topical Prostaglandin Analogs. *Clinical Ophthalmology* 2009;3:637-644.

175-Stewart WC, **Robin AL**, Sharpe ED, Hennessy A, Stewart JA. Glaucoma Clinical Trials. *Ophthalmology*. 2010;117(2):397.

176-Ramulu PY, Do D, Corcoran SL, Corcoran KG, **Robin AL**. Utilization of Retinal Procedures in Medicare Beneficiaries from 1997 to 2007. *Archives of Ophthalmology*, 2010;128 (10):1335-1340.

177-Rathinam SR, Krishnadas R, Ramakrishnan R, Thulasiraj RD, Tielsch JM, Katz J, **Robin AL**#, Kempen JH. Population-based Prevalence of Uveitis in Southern India. *Br J Ophthalmol*, 2011;95:463-467.

178-Hennessy AL, Katz J, Covert D, Protzko C, **Robin AL**. Videotaped Evaluation of Eyedrop Instillation in Glaucoma Patients with Visual Impairment or Moderate to Severe Visual Field Loss. *Ophthalmology* 2010;117:2345-2352.

179-**Robin A**, Grover DS. Compliance and adherence in glaucoma management. *Indian J Ophthalmol*. 2011. Jan;59 Suppl:S93-96.

180-Fingert J, **Robin AL**, Stone JL, Sheetz TE, Alward WLM, Kwon YH, Wassink WH, Sheffield VC, Stone EM.. Copy number variations on chromosome 12q14 that cause normal tension glaucoma. *Human Molecular Genetics*. 2011;doi:10.1093/hmg/ddr123. PMC3098731

181-Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, **Robin AL**. The Relationship Between Glaucoma Medication Adherence, Eye Drop

Technique, and Visual Field Defect Severity. *Ophthalmology*.2011 Dec;118(12):2398-402. PMID: 21856009

182-Hennessy AL, Katz J, Ramakrishnan R, Krishnadas R, Thulasiraj SD, **Robin AL**. Letter to the Editor; Authors Respons:The Utility of Relative Afferent Pupillary Defect as a Screening Tool for Glaucoma: Prospective Examination of a Large Population-based Study in a south Indian Population. *Brit J Ophthalmol*. 2011;95:1326.

183-Sleath B, Blalock SJ, Stone JL, Skinner AC, Covert D, Muir K, **Robin AL**. Validation of a Short Version of the Glaucoma Medication Self-Efficacy Questionnaire. *Brit J Ophthalmol* ,2012, 96; 258-262. PMID: 21610264

184-Hennessy AL, Katz J, Covert D, Kelly CA, Suan EP, Speicher MA, Sund NJ, **Robin AL**. A Video Study Of Drop Instillation In Both Glaucoma And Retina Patients With Visual Impairment. *Am J Ophthalmol*. 2011;152:982-988.

185-Kawase K, Allingham R, Meguro A, Mizuki, Roos, B, Solivan-Timpe FM, **Robin A**; Ritch R; Fingert J. Confirmation of TBK1 duplication in normal tension glaucoma. *Experimental Eye Research*. 2012;96:178-180. PMC3296819

186-Sleath B, Blalock S, Covert D, Skinner AC, Muir K, **Robin AL**. Patient race, reported problems in using glaucoma medications, adherence, and glaucoma medication adherence self-efficacy. *ISRN Ophthalmology*, vol . 2012, Article ID 902819, 7 pages, 2012. doi:10.5402/2012/902819.

187-O'Dell L, Hennessy AL, **Robin AL**. Evaluating Adherence to Ocular Hypotensives Using The Travatan Dosing Aid. *Clinical Optometry*. 2012;4:1-6.

188-Venkatesh R, Sengupta S, **Robin AL**.Mitomycin C Augmented Trabeculectomy Combined with Single Site Manual Small Incision Cataract Surgery Through a Tunnel Flap Technique. *Asia-Pacific Journal of Ophthalmology*. 2012;1:142-146.

189-Fingert J, Darbo B, Qian Q, Van Rheedan R, Miller K, Riker M, Solivan-Timpe F, Roos B, **Robin A**, Mullins R. Expression of TBK1 and Flanking Genes in Human Retina. *Ophthalmic Genetics*. 2013; 1-6. DOI: 10.3109/13816810.2013.768674 PMC3779656

190-Stalmans I, Callanan DG , Dirks MS, Moster MR, **Robin AL**, Van Calster J, Scheib SA, Dickerson JE, Jr., Landry TA,. Bergamini MVW. Treatment of Steroid-Induced Elevated Intraocular Pressure with Anecortave Acetate: A Randomized Clinical Trial. *J Ocular Pharmacology and Therapeutics*.

2012;28 (6); 559-565. DOI: 10.1089/jop.2012.0063

191- Bourne R, Price H, Stevens G, GBD Vision Loss Expert Group. Global burden of visual impairment and blindness. *Arch Ophthalmol*. 2012 May;130(5):645-7.

192-Bourne R, Price H, Taylor H, Leasher J, Keeffe J, Glanville J, Sieving PC, Khairallah M, Wong TY, Zheng Y, Mathew A, Katarav S, Mascarenhas M, Stevens GA, Resnikoff S, Giehuhi S, Naidoo K, Wallace D, Kymes S, Peters C, Pesudoys K, Braithwaite T, Limburg H; Global Burden of Disease Vision Loss Expert Group. New systematic review methodology for visual impairment and blindness for the 2010 Global Burden of Disease study *Ophthalmic Epidemiol*. 2013;20(1):33-9

193- Freedman RB, Jones SK, Lin A, Robin AL, Muir KB. Influence of Parental Health Literacy on Pediatric Glaucoma Medication Adherence. *Arch Ophthalmol*. 2012 Mar; 130(3):306-11. PMID 224111659. doi: 10.1001/archophthalmol.2011.1788.

194-Seo S, Solivan-Timpe F, Roos BR, **Robin AL**, Stone EM, Kwon YH, Alward WLM, Fingert JH. Identification of Proteins that Interact with Tank Binding Kinase 1 (TBK1) and Testing for Mutations Associated With Glaucoma. *Current Eye Research*. 2013; Feb;38(2):310-5. PMC23286385

195- **Robin AL**, Thulasiraj RD. Cataract Blindness [Solicited Editorial]. *Arch Ophthalmol*. 2012; 130(11):1452-5.

196-Ritch R, Darbro B, AJ MD, Khanna CL, Solivan-Timpe F, Roos BR, Sarfarzi M, Kawase K, Yamamoto T, **Robin AL**, Fingert JH. TBK1 Gene Duplication and Normal Tension Glaucoma. *JAMA Ophthalmol*, 2012 Mar;96(1):178-80.

197- Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group. Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. *Invest Ophthalmol Vis Sci*. 2013 Feb 15;54(2):1252-9.

198- Tucker BA, Solivan-Timpe F, Roos BR, Anfinson KR, Robin AL, Wiley LA, Mullins RF, Fingert JH. Duplication of TBK1 Stimulates Autophagy in iPSC-Derived Retinal Cells in a Patient With Normal Tension Glaucoma. *J of*

Stem Cell Research and Therapy.2014, 4;1: <http://dx.doi.org/10.4172/2157-7633.1000161>

199- Sommer A, Taylor HR, Ravilla TD, West S, Leitman T, M Keenan JD, Chiang MF, Robin AL, Mills RP. Challenges of Ophthalmic Care in the Developing World. *JAMA Ophthalmol*. doi:10.1001/jamaophthalmol.2014.84.

200- Ritch R, Darbro B, Menon G, Khanna CL, Solivan-Timpe F, Roos BR, Sarfarzi M, Kawase K, Yamamoto T, Robin AL, Lotery AJ, Fingert JH. TBK1 Gene Duplication And Normal-Tension Glaucoma. *JAMA Ophthalmol*. 2014;132(5):544-548. doi:10.1001/jamaophthalmol.2014.104

201- Sleath B, Slota C, Blalock SJ, Carpenter DM, Muir KW, **Robin AL**. Determinants of self-reported barriers to glaucoma medicine administration and adherence: a multisite study. *Annals of Pharmacotherapy*. 04/2014; DOI:10.1177/1060028014529413

202- Sleath B, Slota C, Blalock SJ, Sayner R, Carpenter DM, Muir KW, **Robin AL**. Provider Use Of Collaborative Goal Setting With Glaucoma Patients. *Optometry and Vision Science*, 2014;91:549-555.

203- Sleath B, Sayner R, Blalock SJ, Carpenter DM, Muir KW, Hartnett ME, Tudor G, Lawrence S, Giangiacomo AL, **Robin AL**. Patient Question-Asking About Glaucoma and Medications During Videotaped Medical Visits. *Health Communication*. [10.1080/10410236.2014.888387](https://doi.org/10.1080/10410236.2014.888387).

204- Sleath B, Blalock SJ, Carpenter DM, Muir KW, Sayner R, Lawrence S, Giangiacomo AL, Hartnett ME, Tudor G, Goldsmith J, **Robin AL**. Provider Education About Glaucoma and Glaucoma Medications During Videotaped Medical Visits. *J Ophthalmol*. 2014;2014: 238939. doi: 10.1155/2014/238939. Epub 2014 Apr 24. PMID:24868450 [PubMed]

205- Newman-Casey PA, Verkade AJ, Oren G, **Robin AL**. Gaps in Glaucoma Care: A Systematic Review of Monoscopic Disc Photos to Screen for Glaucoma. *Expert Rev Ophthalmol*. 2014; 9(6): 467-474.

206- Sleath B, Blalock SJ, Carpenter DM, Sayner R, Muir KW, Slota C, Lawrence S, Giangiacomo AL, Hartnett ME, Tudor G, Goldsmith J, **Robin AL**. Ophthalmologist-Patient Communication, Self-Efficacy, and Glaucoma Medication Adherence. *Ophthalmology*. 2015;122 (4):748-754.

- 207- Saeddi OJ, Luzuriaga C, Elish N, **Robin AL**. Potential Role of E-mail and Text Messaging In Improving Adherence in Glaucoma and Ocular Hypertension. *Journal of Glaucoma*.2014; 24(5):e95-e102. doi: 10.1097/IJG.0000000000000150.
- 208- Slota C, Sayner R, Vitko M, Carpenter DM, Blalock SJ, **Robin AL**, Muir KW, Hartnett ME, Sleath B. Glaucoma Patient Expression of Medication Problems and Nonadherence. *Optom Vis Sci*. 2015; 92:537-543.
- 209- Newman-Casey PA, **Robin AL**, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey. *Ophthalmology* 2015; 122(7):1308-1316. doi: 10.1016/j.ophtha.2015.03.026. Epub 2015 Apr 24.PMID:25912144
- 210- Sayner R, Carpenter DM, Blalock SJ, **Robin AL**, Muir KW, Hartnett ME, Giangiacomo AL, Tudor G, Sleath B. Accuracy of Patient-Reported Adherence To Glaucoma Medications on A Visual Analog Scale Compared With Electronic Monitors. *Clin Ther*. 2015; Jul 8. pii: S0149-2918(15)00862-0. doi: 10.1016/j.clinthera.2015.06.008. [Epub ahead of print] PMID: 26164785.
- 211-Sleath B, Carpenter DM, Blalock SJ, Sayner R, Muir KW, Slota C, Giangiacomo AL,Hartnett ME, Tudor G, **Robin AL** Applying the Resources and Supports in Self-Management Framework to Examine Ophthalmologist-Patient Communication and Glaucoma Medication Adherence. *Health Educ Res*.2015 Oct; 30(5):693-705. doi: 10.1093/her/cyv034. Epub 2015 Sep 2. PMID: 26338986
- 212- Arora KS, **Robin AL**, Corcoran KJ, Corcoran SL, Ramulu PY. Use Of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012.*Ophthalmology*. 2015 Aug;122(8):1615-24. doi: 10.1016/j.ophtha.2015.04.015. Epub 2015 Jun 16.
- 213- Novack GD, **Robin AL**. Ocular Pharmacology. *J Clin Pharmacol*. 2016; (5)May 56(5):517-27. PMID: 26360129
- 214- Newman-Casey PA, **Robin AL**. Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence: an Update in 2015. *Expert Rev Ophthalmol*. 2016; 11(1):5-20. PMID 27134639.

215- Moore DB, Neustein RF, Jones SK, **Robin AL**, Muir KW. Pediatric glaucoma medical therapy: who more accurately reports medication adherence, the caregiver or the child. *Clin Ophthalmol* 2015 (11) 9:2209-2212. PMID:26648687.

216- Carpenter D.M., Blalock S.J., Sayner R., Muir K.W., **Robin A.L.**, Hartnett M.E., Giangiaco A.L., Tudor G.E., Sleath B.L. (accepted for publication) Communication predicts medication self-efficacy in glaucoma patients. *Optometry & Vision Science*. 2016 March 19. [Epub ahead of Print] PMID 27003815

216- Venkatesh R, van Landingham S, Khodifad AH, Haripriya A, Thiel CL, Ramulu P, **Robin AL**. Carbon Footprint and Cost-Effectiveness of Cataract Surgery. *Curr Opin Ophthalmol*. 2016; 27(1): 82-88. PMID 26569528.

217- Do AT, Pillai MR, Ballakrishnan V, Chang RT, **Robin AL**, Singh K, Effectiveness of Glaucoma Counseling on Rates of Follow up and Glaucoma Knowledge in a South Indian Population. *Am J Ophthalmol* 2016;March; 163: 180-189. E.4. PMID 26705095.

218-Sengupta S, Venkatesh R, Krishnamurthy MS, Nath M, Mashruwala A, Ramulu P, **Robin AL**, Lee P. Intraocular Pressure Reduction after Phacoemulsification versus Manual Small-Incision Cataract Surgery: A Randomized Control Trial. *Ophthalmology*. 2016; 123:1695-1703.

219- Kader MA, Namburi P, Ramugade S, Ramakrishnan R, Krishnadas SR, Roos BR, Periasamy S, **Robin AL**, Fingert JH. Clinical and Genetic Characterization of a large primary open angle glaucoma Pedigree. *Ophthalmic Genetics*. 2016: published on line <http://dx.doi.org/10.1080/13816810.2016.1193883>

220- Le HG, Ehrlich JR, Venkatesh R, Srinivasan A, Koli A, Haripriya A, Ravindran RD, Thulasiraj RD, **Robin AL**, Hutton DW, Stein JD. A Sustainable Model for Delivering High-Quality, Efficient Cataract Surgery in

Southern India. *Health Aff (Millwood)*. 2016 Oct 1;35(10):1783-1790.
PMID:27702949.

221: **Robin AL**. Public Health Policy Lessons From Oklahoma. *JAMA Ophthalmol*. 2016 Oct 1;134(10):1102-1103. Doi:10.1001/jamaophthalmol.20162573. PMID: 27468094.

222- Fingert JH, **Robin AL**, Sheetz TE, Kwon YH, Liebmann JM, Ritch R, Alward WLM. Tank-Binding Kinase 1 (TBK1) Gene and Open-Angle Glaucoma (An American Ophthalmological Society Thesis). *Trans Am Ophthalmol Soc*. 2016;114: T6 [1-11]

223- Schehlein EM, Novack GD, **Robin AL**. New Classes of Glaucoma Medications. *Curr Opin Ophthalmol*. 2016 Nov 8 [Epub ahead of print] PMID:27828896

224- Sleath B, Sayner R, Vitko M, Carpenter DM, Blalock SJ, Muir KW, Giangiacomo AL, Hartnett ME, **Robin AL**. Glaucoma Patient-Provider Communication About Vision Quality-Of-Life. *Patient Educ Couns*. 2016 Nov 22. pii: S0738-3991(16)30545-6. doi: 10.1016/j.pec.2016.11.018. [Epub ahead of print] PMID:27916461

225- **Robin AL**, Ravilla T, Venkatesh R. Combatting Cataract Blindness. *JAMA Ophthalmol*. 2016;112(11) Dec 15. doi: 10.1001/jamaophthalmol.2016.4779. [Epub ahead of print]. PMID: 27978572

226- Schehlein EM, Im LT, **Robin AL**, Onukwugha E, Saedi OJ. Nonmedical Out-Of-Pocket Patient and Companion Expenditures Associated with Glaucoma Care. *J of Glaucoma*. 2017 Apr;26(4):343-348. doi: 10.1097/IJG.0000000000000619. PMID:28355174

227- Vardhan S A, Haripriya A, Ratukondla B, Ramulu P, Shivakumar C, Nath M, Vijayaraghavan P, **Robin AL**. Association of Pseudoexfoliation with Systemic Vascular Diseases in a South Indian Population. *JAMA Ophthalmol*. 2017;135(4):348-354. doi:10.1001/jamaophthalmol.2017.0064 PMID: 28278318

228-Barneby HS, **Robin AL**. Adherence to Fixed Combination versus unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. *Am J Ophthalmol*. 2017;176:61–69. PMID:27993589

229- Jeganathan VSE, **Robin AL**, Woodward MA. Refractive Error in Underserved Adults: Causes and Potential Solutions. 2017 Jul; 28(4):229-304. doi: 10.1097/ICU.0000000000000376. Review. PMID: 28379859

230- Robin AL, Stein JD. RE: Haripriya et al.: Long-term posterior capsule opacification with square-edge polymethylmethacrylate intraocular lens: randomized controlled study. *Ophthalmology*. 2017;124:295-302). *Ophthalmology*. 2017 Jul;124(7):e60-e61. doi:10.1016/j.ophttha.2017.03.006..PMID:28645350

231- Davila JR, Sengupta SS, Niziol LM, Sindal MD, Besirli CG, Upadhyaya S, Woodward MA, Venkatesh R, **Robin AL**, Grubbs J Jr, Newman-Casey PA. Predictors of Photographic Quality with a handheld Nonmydriatic Fundus Camera Used for Screening Vision-Threatening Diabetic Retinopathy. *Ophthalmologica*. 2017;238(1-2):89-99. doi: 10.1159/000475773. Epub 2017 Jul 5. PMID: 28675903

232- Miller SE, Thapa S, **Robin AL**, Niziol LM, Ramulu PY, Woodward MA, Paudyal I, Pitha I, Kim TN, Newman-Casey PA. Glaucoma Screening in Nepal: Cup-to-Disc Estimate With Standard Mydriatic Fundus Camera Compared to Portable Nonmydriatic Camera. *Am J Ophthalmol*. 2017 Oct;182:99-106. doi: 10.1016/j.ajo.2017.07.010. Epub 2017 Jul 19. PMID: 28734816

233- Johnson CA, Thapa S, George Kong YX, **Robin AL**. Performance of an iPad Application to Detect Moderate and Advanced Visual Field Loss in Nepal. [Am J Ophthalmol](#). 2017 Oct;182:147-154. doi: 10.1016/j.ajo.2017.08.007. Epub 2017 Aug 25. PMID: 28844641

234- Sengupta S, Sindal MD, Besirli CG, Upadhyaya S, Venkatesh R, Niziol LM, **Robin AL**, Woodward MA, Newman-Casey PA. Screening for vision-threatening diabetic retinopathy in South India: Comparing Portable non-Mydriatic and standard Fundus Cameras and Clinical Exam. *Eye (Lond)*. 2017 Sep 15. doi: 10.1038/eye.2017.199. [Epub ahead of print]. PMID:28912515

235- DeLuca AP, Wallace LMA, Liebmann J, Ritch R, Kawase K, Kwon YH, **Robin AL**, Stone EM, Scheetz TE, Fingert JH. Genomic Organization of TBK1 Copy Number Variations in Glaucoma Patients. *J Glaucoma*. 2017 Dec;(26)12:1063-1067. doi: 10.1097/IJG.0000000000000792. PMID:28984711

236- Thiel CL, Schehlein E, Ravilla T, Ravindran RD, Robin AL, Saeedi OJ, Schuman JS, Venkatesh R. Cataract Surgery & Environmental Sustainability: Waste & Life Cycle Assessment of Phacoemulsification at Aravind Eye Care System. *J Cataract and Refractive Surg.* 2017;43:1391-1398.

Non-Peer Reviewed Publications

Robin AL. Medical therapy to prevent intraocular pressure rise associated with argon laser trabeculoplasty. *Ophthalmology Digest* 1: 12, 1991

ROBIN AL Initial Medical Therapy for Primary Open-Angle Glaucoma. *Ophthalmic Practice* 2002; 20: 270-273.

Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. *Ophthalmology Digest* 1989;1:13-14.

XIV. Books

Ramakrishnan R, Krishnadas SR, Khurana M, **Robin AL.** Diagnosis and Management of Glaucoma. Jaypee-Highlights Medical Publishers. 2012. Panama City.

XV. Book Chapters

1-**Robin AL:** Laser iridotomy: Historical perspective. In: Jacob T. Wilensky, ed. Laser Therapy in Glaucoma. E. Norwalk, Conn: Appleton-Century-Crofts, 1985; pp. 59-62.

2-**Robin AL:** Trabeculotomy. In: Jacob T. Wilensky, ed. Laser therapy in glaucoma. E. Norwalk, Conn: Appleton-Century Crofts, 1985; pp. 131-135.

3-Pollack IP, **Robin AL:** Laser trabeculoplasty: Indications. In: Jacob T.

Wilensky, ed. Laser Therapy in Glaucoma. E. Norwalk, Conn: Appleton-Century-Crofts, 1985; pp. 9-15.

4-**Robin AL**, Pollack IP: Q-switched neodymium:YAG laser iridotomy. In: Atlas of Ophthalmic Surgery: Cornea Glaucoma Lens Vol 2, Spaeth and Koch eds. Georg Thieme, New York,1987; pp. 2.48-2.49.

5-Pollack IP, **Robin AL**, Lynch MG: Laser surgery in open-angle glaucoma. In: GW Weinstein, ed. Contemporary Issues in Ophthalmology: Open-Angle Glaucoma Vol 3. NY, NY: Churchill Livingstone, Inc., 1986; pp 227-250.

6-**Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc., 1985.

7-**Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc., 1986.

8-**Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc. 1987.

9-**Robin AL**: Q-switched neodymium:YAG laser iridotomy. Coherent Medical Group, Palo Alto, California, 1987.

10-**Robin AL**, Pollack IP: Uses of ALO 2145 in anterior segment glaucoma surgery. In: Shields MB, Pollack IP, Kolker AE, eds. Perspectives in Glaucoma: Transactions of First Scientific Meeting of the American Glaucoma Society. Philadelphia: Slack, 1988; 271-279.

11-Pollack IP, **Robin AL**, Streisfeld DL, Del Priore L, Jampel HD, Green WR, Quigley HA, Schwartz D, and D'Anna S: Neodymium:YAG Laser: Histopathology of effects upon monkey trabecular meshwork and role in the treatment of open-angle glaucoma. In: GK Krieglstein, ed. Transactions of the International Glaucoma Committee, Glaucoma Update 1987. Springer-Verlag Berlin Heidelberg, 1987; pp. 185-193.

12-**Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc., 1988.

13- **Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc., 1989.

14-**Robin AL**, ed. Winter Glaucoma Symposium. Newtown, PA: Associates in Medical Marketing Co., Inc. 1990.

- 15-**Robin AL**, Novack GD: Alpha₂-Agonists in the Therapy of Glaucoma. In: Drance SM, Neufeld AH, VanBuskirk EM. Glaucoma: Applied Pharmacology in Medical Treatment. Williams and Williams, Baltimore, pp. 103-124, 1992.
- 16-Gieser SC, Juzych M, Schwartz G, **Robin AL**. Adrenergic Drugs for the treatment of Glaucoma. In: Ritch R, Shields MB, Krupin T: *The Glaucomas*, Mosby, St. Louis, 1996, pp 1425 to 1448. (2nd edition).
- 17-Juzych M, **Robin AL**, Novack GD. Alpha-2 Agonists in Glaucoma Therapy. In: Zimmerman T, Kooner K, Sharir M: *Textbook of Ocular Pharmacology*. Lippincott-Raven Publishers, Philadelphia, 1997. Pp 247 - 254.
- 18-Juzych MS, Zimmerman TJ, Robin AL. Update on Adrenergic Agents in Glaucoma Therapy. *Ophthalmology Clinics of North America* 1997;10:309-326.
- 19-Wax MB, Novack GD, **Robin AL**. Adrenergic Agents. *Principles and Practice of Ophthalmology*. Daniel Albert, MD, and Frederick Jacobiec MD. WB Saunders Co., Philadelphia, PA.
- 20-Robin AL, Novack GD, Choplin NT. "Medical Therapy for Glaucoma" in Atlas of Glaucoma. Choplin NT and Lundy DC eds. Martin Dunitz, LTD., London, UK, 1998 pps 203-220.
- 21-Savage H, **Robin AL**. . "Adrenergic Agents" in Ophthalmology Monograph 13, Glaucoma Principles and Management. Edited by Peter A. Netland and Robert C. Allen. American Academy of Ophthalmology, San Francisco. 1999 pps 47-75.
- 22-Robin Todd A., **Robin AL**. "The Aravind Eye Care System: Equitable Development for Sustainable Eye Care Services in India." Chap 29. In: Section 13 ("International Ophthalmology") of Basic and Clinical Science Course. San Francisco: American Academy of Ophthalmology, 2002.
- 23-Marcic TS, **Robin AL**. Argon and Nd:YAG peripheral iridotomy. In Surgical Techniques in Ophthalmology: Glaucoma Surgery. Chen T editor. Saunders Elsevier Philadelphia. pp 217-224
- 24-Robin AL, Budenz DL, Congdon NG, Thulasiraj RD. "Practical application of glaucoma care in different societies". In: Shaarawy TM,

Sherwood MB, Hitchings RA, Crowston JG. *Glaucoma*. Saunders Elsevier, London, 2009. Pp. 33-42.

25-Grover DS, **Robin AL**. “How frequent is corticosteroid-induced glaucoma? How should I manage it?” In: Heuer DK, Gedde SJ, Lewis RA, Chang DF. *Curbside Consultation in Glaucoma*. Slack Inc. NJ. 2008. Pp 105-108.

26- **Robin AL**, Budenz DL, Congdon NG, Thulasiraj RD. “Practical application of glaucoma care in different societies”. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG. *Glaucoma: a Medical Diagnosis & Therapy*. Second Edition. Elsevier, London, 2015. Pp. 33-42.

27- Novack GD, Muir KW, Newman-Casey PA, **Robin AL**. Ocular Hypotensive Medications: Adherence and Performance IN: *GLAUCOMA*, 2nd edition, Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (eds), Elsevier, NY. Chapter 47 (page 521-524).

28- Grover DS, **Robin AL**. “How frequent is corticosteroid-induced glaucoma? How should I manage it?” In: Gedde SJ, Heuer DK, Lewis RA, Panarelli JF. *Curbside Consultation in Glaucoma*. Slack Inc. NJ. 2015. Pp 30-35.

XVI. Major Invited Speeches:

1-Visiting Professor University of Illinois: 1982, 1983, 1989

2-Visiting Professor University of South Florida: 1983, 1984, 1985

3- Visiting Professor New York Eye and Ear Infirmary: 1983

4-IVth International Laser Symposium: (Detroit, Michigan) 1983

4-International Glaucoma Symposium (Jerusalem, Israel): 1983

5-Visiting Professor, Creighton University: 1983

6- Visiting Professor, Howard University: 1984

- 7-National Society for the Prevention of Blindness Symposium at the American Academy of Ophthalmology: 1984, 1990
- 8- Invited Speaker: Washington Hospital Center: 1985, 1988, 1991
- 9- Visiting Professor-University of Maryland: 1985
- 10- Phillips Eye Institute, Minneapolis, MN: 1985
- 11-Guest Lecturer: Alaska Native Medical Center, Anchorage, Alaska: 1985
- 12-Guest Lecturer, American Intraocular Lens Society, Boston, Mass: 1985
- 13- Guest Lecturer, Wilmer Institute, Johns Hopkins University: "Glaucoma '86": 1986
- 14- Invited speaker, National Council for International Health, Washington, DC: 1986
- 15-Case Western Reserve University, "Glaucoma Update 1986", 1986
- 16- Invited speaker. International Association for the Prevention of Blindness, New Delhi, India; 1986
- 17-Ocular Drug Update on Beta-Blockers, Philadelphia, PA; 1986
- 18-Ocular Drug Update on Non-steroidal Anti-inflammatory drugs, New Orleans; 1986.
- 19-New Developments in Ocular Therapy, Sinai Hospital, Baltimore, Maryland; March, 1987.
- 20-Invited speaker, American Glaucoma Society, Iowa City, Iowa; 1987.
- 21- University of California, Irvine, (Ocular Drug Therapy Update); 1987, 1988.
- 22-American Academy of Ophthalmology, Discussion of: Silverstone DE, Novack GD, Kelley E, et al. Prophylaxis Against Post-Surgical and Post-YAG Laser Intraocular Pressure Spikes with Levobunolol, 1987.
- 23-Washington Hospital Center Spring Symposium: "Advances in Glaucoma": April, 1988; April, 1996.
- 24-Third Congress of the European Glaucoma Society: Estoril, Portugal: May, 1988.
- 25-University of California, Davis. "Glaucoma: Under Pressure": 1988.
- 26-Royal Hawaiian Eye Meeting: Kauai, Hawaii, 1989.

- 27-Louisiana State University: 1989.
- 28-Invited Speaker, Nepal Eye Hospital, Kathmandu, Nepal: 1989.
- 29-Invited Speaker, Georgia Ophthalmological Society: 1990.
- 30-Chairman, Glaucoma Society of the International Congress of Ophthalmology, Singapore: 1990.
- 31-Invited Speaker, International Congress of Ophthalmology, Singapore: 1990.
- 32-American Academy of Ophthalmology, Discussion of: Yaldo MK, Shin DH, Lee SY. The Additive Effects of 1% Apraclonidine to Non-Selective Beta-Blockers, 1990.
- 33-Visiting Professor, Duke University: 1991.
- 34-University of California, San Diego: 1991.
- 35-Invited speaker, New York City Laser Society: 1991
- 36-Visiting Professor, Massachusetts Eye and Ear Infirmary, 1991.
- 37- Visiting Professor, C.U. Shah Ophthalmic Post Graduate Training Centre Medical Research Foundation; Madras, India: 1991.
- 38-Visiting Professor, Tufts University, 1991.
- 39-Guest Speaker, South East Asian Regional Conference, Kathmandu, Nepal; 1991.
- 40- Guest Speaker, Aravind Eye Hospital and Postgraduate Center, Madurai, India; 1991, 1992.
- 41- Guest Speaker, American Osteopathic College of Ophthalmology and Otolaryngology, Washington, DC; 1992.
- 42- Panelist and Guest Lecturer, American Society of Cataract and Refractive Surgery, San Diego, 1992.
- 43- Guest Speaker, Michigan Ophthalmologic Society, 1992.
- 44- Invited speaker, International Society of Eye Research, Stresa, Italy. 1992.
- 45-Guest speaker, Maryland Society of Eye Physicians and Surgeons, Columbia and Annapolis, Maryland. 1992,1993.

- 45- Panelist and Invited speaker, All India Glaucoma Society. Invited Guest. Madras, India. 1993.
- 46- Invited speaker, 48th Japanese Congress of Clinical Ophthalmology. November 5, 1994.
- 47- American Academy of Ophthalmology and American Glaucoma Society: "Under Pressure". October 29, 1994." Talk entitled "Alpha-agonists: The latest additions".
- 48- Invited Speaker, Emory University Resident's Day, June 10, 1995.
- 49- Invited speaker, European Glaucoma Society, June 25, 1995; Milan, Italy.
- 50- Section Co-Chairman; International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics, September 30, 1995; Geneva, Switzerland.
- 51- International Congress on Glaucoma: Decision Making in Therapy (University eye Clinic of Rome "Tor Vergata"; February 2-4, 1996.
- 52- Arthur D. Culler Lecture at the 19th Annual Midwest Glaucoma Symposium, Columbus Ohio, March, 1996.
- 53- Invited lecturer; American Ophthalmological Society: 1993, 1994, 1996
- 54- Invited speaker, XII International Congress Of Ophthalmology, September, 1996, Yokohama, Japan.
- 55- Invited speaker, VI All India Glaucoma Society, October, 1996, Madurai, India.
- 56- Invited speaker, Maryland Society of Physicians and Surgeons, 1996 Scientific Assembly: "What's Up in Ophthalmology Besides the Pressure"; September 20, 1996.
- 57- Section chair, organizer, and speaker: University of Maryland, Surgical Dilemmas in Glaucoma Management, Baltimore, February 23, 1996.
- 58- University of Maryland, "Advances in Laser Applications For Ophthalmology", Baltimore, September 27, 1996.
- 59- American Academy of Ophthalmology Symposium "International Ophthalmology: New Aspects of Old Problems": Glaucoma, one of the most difficult problems - Detecting Glaucoma, Approaches and Effectiveness. Wednesday October 30, 1996.
- 60- Invited Guest; Philadelphia Ophthalmology Society, Philadelphia, PA. February 1997.
- 61- University of Maryland: Diagnostic and Therapeutic Advances in Glaucoma Management. February 21, 1997; Baltimore, Maryland.

- 62- Guest of Honor; All India Ophthalmological Society- Key note address. February 23, 1977. Delhi, India.
- 63- Visiting Professor, Harkness Eye Institute, Columbia University. New York City, New York. April 6, 1997.
- 64- Visiting Professor, Lunds Universitet- Malmö University Hospital, Malmö Sweden; May, 1997.
- 65- Visiting Professor, University of Uppsala, Sweden; May, 1997.
- 66- Visiting Professor, University of Göttingen, Sweden; May, 1997.
- 67- Guest of honor, St. Erick's Hospital, Stockholm Sweden, May, 1997.
- 68- Guest Speaker, Maryland Optometric Association, Annual Meeting. June 1997.
- 69- Invited guest, Florida Ophthalmological Society: Fort Lauderdale, September 1997.
- 70- Invited Guest, Central Pennsylvania Ophthalmological Association, November 1997; Harrisburg, PA.
- 71- American Academy Of Ophthalmology:
Discussion of: Latanoprost as Additional or Replacement Therapy for Glaucoma.
Rothman RF, Marcus C, Greenfield DS, Liebman JM, Prywes AS, Udell IJ, Ritch R.
October 1997.
- 72- Janice Kushner Memorial Annual Lecture, International Glaucoma Society. London, England, November, 1997.
- 73- Visiting Professor, Washington University, St. Louis Missouri. January, 1998.
- 74- Guest speaker: St. Louis Ophthalmological Society Lecture, January 1998.
- 75- Honored Lecturer; New England Ophthalmological Society (NEOS). Boston, Mass. 1998 and 2010.
- 76- Guest Lecturer Chicago Glaucoma Society, May 6, 1998.
- 77- Guest Lecturer, Delaware Ophthalmological Society, June, 1998.
- 78- Visiting Professor, Albert Einstein School Of Medicine, June, 1998.

- 79-Invited Speaker In Glaucoma Symposium, 28th International Congress of Ophthalmology, Amsterdam, June, 1998.
- 80-28th Invited Speaker in International Prevention of Blindness Symposium, International Congress of Ophthalmology, Amsterdam, June, 1998.
- 81-Invited speaker, Second International Symposium on “The Challenges and Controversies of Ophthalmology and Visual Sciences in the Next Millennium”, Hong Kong, August 1998.
- 82-Key Note Speaker, Indian Glaucoma Society; Nagpur, India October 1998.
- 83-Invited Speaker, Ocular Surgery News Update in Glaucoma, New York, New York; October, 1998.
- 84-Key Note Speaker, Association of Asian American Indians in Ophthalmology, New Orleans. November, 1998.
- 85-Discussant of Beaver Dam Eye Study Visual Field Analysis: Normal Intraocular Pressure is Common in Eyes with Field Loss and Cupped Discs by William Eric Sponsel. At the American Academy of Ophthalmology 1998 Annual Meeting, November 10, 1998, New Orleans.
- 86-Invited Keynote Speaker and Section Leader on Advances in Glaucoma, All India Ophthalmological Society, Cochin India, January, 1998.
- 87-Visiting Professor, Ohio State University, February 1999
- 88-Brown Memorial Lectureship, Ohio State University, February 1999.
- 89-Moderator, Glaucoma Pharmacology Section, Association for Research in Vision and Ophthalmology (ARVO) May 1999.
- 90-Section Leader: Fifth Update in Ophthalmology for Postgraduate Students. July 1999. Aravind Eye Hospital, Madurai India.
- 91-Visiting Professor, University of Western Ontario, Canada. September 1999.
- 92-Key Note Speaker, 53rd Congress of Clinical Ophthalmology of Japan, Tokyo, October 1999.
- 93-Key Note Speaker, 2nd Asian-Oceanic Glaucoma Society. Tokyo, October 1999.
- 94- Keynote speaker, All India Society of Ophthalmology, Annual Meeting, Chennai India January 2000.

- 95- Visiting Professor, Yale University, 2000..
- 96- Visiting Speaker, Delaware Academy of Ophthalmology, March 23, 2000..
- 97- Visiting Professor, Oregon Health Sciences University, Portland, Oregon. April 7, 2000.
- 98- Bausch and Lomb visiting Professor University of Rochester; Rochester New York., October 14, 2000.
- 99-Keynote speaker and section leader. Tenth Annual Indian Glaucoma Society, Chandrigar India. November 2000.
- 100- Participant, South East Asian Glaucoma Special Interest Group. Bangkok, Thailand. November 30, 2000.
- 101-Invited speaker, Chicago Glaucoma Society, May 2001.
- 102-Key Note Speaker: Colorado Society Of Eye Physicians and Surgeons. July 2001.
- 103-Key Note Speaker, Pan American Academy of Ophthalmology Glaucoma Symposium. Buenos Aires, October 2001.
- 104- Invited speaker, Dallas Ophthalmology Association. September, 2001.
- 105-Visiting Professor, Southwestern University. September 2001.
- 106- Invited speaker, Philadelphia Ophthalmic Club, guest speaker. October 2001.
- 107- Section Leader and Presenter, European Association For Vision and Eye Research.. Alicante, Spain October 2001.
- 108-Invited Speaker, American Glaucoma Society, San Juan. March 2002.
- 109-Invited Speaker, International Congress of Ophthalmology, Sydney, Australia, 2002.
- 110-Invited Speaker, American Ophthalmological Society, Sea Isle Georgia, 2002.
- 111-Poster, ARVO, Fort Lauderdale Florida, May, 2002.
- 112- Invited Speaker, American Ophthalmological Society, May, 2002.
- 113- Symposium Coordinator, EVER, Alicante Spain; October 2002.
- 114-Visiting Professor, Indian Glaucoma Society, New Delhi, India; 2002.

- 115-Invited Speaker, Brazil Glaucoma Society, Sao Paulo; April, 2003.
- 116- Invited speaker, 37th Pan-Hellenic Ophthalmological Society Meeting: Porto Carras, Greece; June 9 to June 16, 2004.
- 117- Honored guest, Ohio Ophthalmology Society. Columbus, Ohio. February, 2005.
- 118-Pan American Ophthalmological Society, Santiago, Chile. Honored Guest; March, 2005.
- 119- Honored guest, Argentina Glaucoma Society, Buenos Aires, Argentina. July, 2005.
- 120-Japan Glaucoma Society, Featured Speaker. Kumamoto, Japan. September, 2005.
- 121- Section head Lindberg Society, World Ophthalmology Congress, Sao Paulo Brazil, February 2006.
- 122- Guest of honor,39th Panhellenic Ophthalmological Congress, Thessaloniki, Greece June 7 to 11 2006.
- 123-Keynote Speaker, Duke University Glaucoma Day, Duke University, September 2006.
- 124- Guest speaker, Royal Hawaiian Eye Meeting. Kauai, Hawaii. January, 2007.
- 125- Guest Speaker, Puerto Rican Ophthalmologic Society, February 2007.
- 126- Guest of Honor, ANZIG (Australian New Zealand Glaucoma Interest Group), Adelaide, Australia. March 2007.
- 127-Invited speaker, EVER (European Vision Eye Research), Slovenia, October, 2007.
- 128-Guest Speaker and Speaker of the Day, Royal Hawaiian Eye Society, January 2008.
- 129- Guest speaker, Royal Hawaiian Eye Society, January 2009 and January 2010,
- 130-Guest of honor, Glaucoma Research Society, Queenstown New Zealand, February 2008.
- 131-Invited speaker, American Glaucoma Society, Washington DC, February 2008.
- 132- Invited speaker, Mid West Glaucoma Society, Omaha Nebraska, May 2008.
- 133- Visiting Professor, Harvard University, April, 2008.
- 134- Visiting Professor, Yale University, November, 2009.

- 135-Visiting Professor, University of Florida, February, 2010.
- 136-Consultant, Alliance for Aging Research, Washington, DC; November 2010.
- 137-Invited Guest, 5th International Congress on Glaucoma Surgery; Delhi, India; November, 2010.
- 138-Invited Guest, LA Ophthalmological Society Research Club, January 2011.
- 139-Invited Lecture, 69th Annual Conference of the All Indian Ophthalmological Society, Ahmedabad, India; February, 2011.
- 140-Wolfe Lecture, University of Iowa, Iowa City, Iowa; 2011.
- 141-Invited Guest, Tamil Nadu Ophthalmology Society, 2011 Tamil Nadu, India.
- 142-Glaucoma Society of India, 2011, Mumbai, India
- 143-Invited Lecturer: Moorfield's International Glaucoma Society, 2012 January. London, England.
- 144-Invited speaker, American Ophthalmological Society, 2012.
- 145-Invited Guest: 70th Conference of the All Indian Ophthalmological Society, Cochin, India. February, 2012.
- 146-Glaucoma Research Society, Speaker on Outcomes and Measurements. Wurzburg Germany, September, 2012.
- 147-International Glaucoma Society, Speaker on CLASS. Glasgow Scotland, September 2012.
- 148- Co-Chair for Glaucoma Sub-specialty day, Joint meeting of American Academy of Ophthalmology-Asian Pacific Association of Ophthalmology-All Indian Ophthalmic Society Section Hyderabad, India; January 17, 2013.
- 149- Invited Guest Speaker American Ophthalmological Society 2013-15.
- 150-First International In-House Scholar, University of Michigan, Ann Arbor; September, 2013.
- 151-Guest of Honor, Irish Ophthalmological Society, Galway Ireland; September, 2013
- 152- Glaucoma Day, American Academy of Ophthalmology, Invited Speaker. October, 2014.

- 153- National Society to Prevent Blindness: Shaffer Lecturer. 2014 American Academy of Ophthalmology Meeting Chicago, IL.
- 154- Guest Lecture, Nepal Ophthalmological Society, Kathmandu, Nepal; January, 2015.
- 155- Visiting Professor, Vanderbilt University, April 2015.
- 156- Invited speaker, Glaucoma Research Society, Seoul, South Korea. September, 2016.
- 157- Invited Speaker, Saudi Ophthalmological Society, Riyadh, Saudi Arabia. April, 2017.
- 158- Invited Speaker, American Society Cataract and Refractive Surgery, Los Angeles. May 2017.
- 159- Invited Speaker, American Ophthalmological Society, May, 2017. Homestead, Virginia.
- 160- Invited Speaker, World Glaucoma Association. June 2017. Helsinki, Finland
- 161- Invited Speaker, Washington Ophthalmological Society. October, 2017.

XVII. Non Proffered Talks

Sinai Hospital (Baltimore, MD): 1983, 1984, 1988, 1989, 1990

St. Elizabeth's Medical Center (Dayton, Ohio): 1984

Greater Baltimore Medical Center: 1984, 1988, 1991

Alcon Surgical Skills Transfer Course. June 1997, Baltimore, MD.

XVIII. Films

- 1- ROBIN AL: Laser peripheral iridectomy. EYESAT vol 16, 1983.
- 2- ROBIN AL: Glaucoma: patient education. Millner-Fenwick, 1983.
- 3- ROBIN AL: Laser iridectomy: patient education. Millner-Fenwick, 1984.
- 4- ROBIN AL: Argon laser trabeculoplasty: patient education. Millner-Fenwick, 1984.

- 5- ROBIN AL: Q-switched neodymium:YAG laser iridectomy. Alcon, 1985.
- 6- ROBIN AL: After eye surgery. Millner-Fenwick, 1985.
- 7- ROBIN AL: Open Angle Glaucoma. Millner-Fenwick, 1992.
- 8- ROBIN AL: Laser Surgery for Open Angle Glaucoma. Millner-Fenwick, 1992.
- 9- ROBIN AL: Angle Closure Glaucoma. Millner-Fenwick, 1992.

XIII. Lectures and Courses at annual meetings

Wilmer Resident's Association: 1976, 1977, 1979-1992.

Association For Research in Vision and Ophthalmology: 1979, 1981-1994.

Moderator: Annual Mid-Winter Glaucoma Symposium (Director): 1985-1991.

American Academy of Ophthalmology: Course entitled "Use of Lasers in the treatment of Glaucoma", 1982-1990, 1992-1995.

American Academy of Ophthalmology: Course entitled "Practical Applications of Laser therapy", 1988-1995.

American Academy of Ophthalmology, invited speaker to National Symposium to Prevent Blindness Symposium, 1990.

American Academy of Ophthalmology, paper discussant, 1990.

American Academy of Ophthalmology: Presenter of invited paper, 1994, 1998.

American Ophthalmologic Society, 1990.

American Academy of Ophthalmology: Course entitled " Laser Applications in Glaucoma: Theory and Practice, 1990-1992.

Florida Society of Ophthalmology, September 1997; "Goals for Glaucoma in the 21st Century"
American Ophthalmological Society; May 2002

25th Anniversary Aravind Glaucoma Service, Pondicherry India. October 2017.

XIV. PATENT APPLICATIONS

20060173437 - Surgical Method August 3, 2006

An irrigating technique that can be used to increase the flow of fluid through the trabecular meshwork. Pulses of relatively high pressure irrigating are directed at the trabecular meshwork. These pulses can be focused, thereby perforating the trabecular meshwork, or applied over a larger area so as to stimulate the trabecular meshwork for improved fluid transport. In addition, the pulses of the irrigating balance salt solution can be used to clean away material, such as iris pigment, that may be blocking or clogging the trabecular meshwork. Such a technique may be practiced using the herein disclosed tip with commercially available surgical handpieces.